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ABSTRACT OF THE DISSERTATION
Knowledge Driven Approaches and Machine Learning Improve the Identification of Clinically
Relevant Somatic Mutations in Cancer Genomics
by
Benjamin John Ainscough
Doctor of Philosophy in Biology and Biomedical Sciences
Human and Statistical Genetics
Washington University in St. Louis, 2017
Professor Obi L. Griffith, Chair
Professor Elaine R. Mardis, Co-Chair

For cancer genomics to fully expand its utility from research discovery to clinical adoption,
somatic variant detection pipelines must be optimized and standardized to ensure identification
of clinically relevant mutations and to reduce laborious and error-prone post-processing steps. To
address the need for improved catalogues of clinically and biologically important somatic
mutations, we developed DoCM, a Database of Curated Mutations in Cancer (http://docm.info),
as described in Chapter 2. DoCM is an open source, openly licensed resource to enable the
cancer research community to aggregate, store and track biologically and clinically important
cancer variants. DoCM is currently comprised of 1,364 variants in 132 genes across 122 cancer
subtypes, based on the curation of 876 publications. To demonstrate the utility of this resource,
the mutations in DoCM were used to identify variants of established significance in cancer that
were missed by standard variant discovery pipelines (Chapter 3). Sequencing data from 1,833
cases across four TCGA projects were reanalyzed and 1,228 putative variants that were missed
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in the original TCGA reports were identified. Validation sequencing data were produced from 93
of these cases to confirm the putative variant we detected with DoCM. Here, we demonstrated
that at least one functionally important variant in DoCM was recovered in 41% of cases studied.
A major bottleneck in the DoCM analysis in Chapter 3 was the filtering and manual review of
somatic variants. Several steps in this post-processing phase of somatic variant calling have
already been automated. However, false positive filtering and manual review of variant
candidates remains as a major challenge, especially in high-throughput discovery projects or in
clinical cancer diagnostics. In Chapter 4, an approach that systematized and standardized the
post-processing of somatic variant calls using machine learning algorithms, trained on 41,000
manually reviewed variants from 20 cancer genome projects, is outlined. The approach
accurately reproduced the manual review process on hold out test samples, and accurately
predicted which variants would be confirmed by orthogonal validation sequencing data. When
compared to traditional manual review, this approach increased identification of clinically
actionable variants by 6.2%. These chapters outline studies that result in substantial
improvements in the identification and interpretation of somatic variants, the use of which can
standardize and streamline cancer genomics, enabling its use at high throughput as well as
clinically.

xii

Chapter 1: Introduction and Background
1.1 Introduction
Cancer is the second leading cause of death in the United States and is a devastating disease
caused by genetic alterations that lead to uncontrolled cell growth and proliferation in various
tissues and organs of the body. Although improvements in cancer detection and treatment have
improved outcomes for many cancer types, this disease remains a significant killer. In their
seminal paper, Hanahan and Weinberg described six traits or “hallmarks”, that make cancer cells
unique from normal cells, including: uncontrolled growth (“self-sufficiency in growth signals”),
lack of response to inhibitory signals (“insensitivity to antigrowth signals”), evasion of cell death
(“evading apoptosis”), uncontrolled cell division (“limitless replicative potential”), stimulated
development of vasculature (“sustained angiogenesis”), and spread to other tissues (“tissue
invasion and metastasis”)1. In 2011, Hanahan and Weinberg updated their paper to include 4
additional hallmarks: (1) abnormal metabolic pathways, (2) immune system evasion, (3) genome
instability, and (4) inflammation2. These hallmarks develop from alterations in the genome or
epigenome that, in normal cells, carry the instructions for normal cell biology. These alterations
can occur in the germline or in differentiated cells (somatic), and act to change normal cell
biology to exhibit one or more hallmarks, leading to cancer onset and progression. One primary
reason for updating the hallmarks was that new types of genomic and epigenomic alterations,
along with many that were already known, were revealed by large-scale discovery genomics in
cancers, facilitated by massively parallel sequencing (MPS) and computational approaches to
discover different types of alterations.

1

Relevant types of alterations include: single nucleotide variants (SNVs), insertions and
deletions (INDELs), and structural variants (SVs). SNVs are the most easily identified type of
genomic variant and are single nucleotide substitutions (point mutations) that may or may not
change the amino acid sequence when they occur in a protein coding gene. INDELs are small (150bp) insertions of novel sequence or deleted nucleotides and typically have deleterious effects
on amino acid sequences when they occur in genes and affect the translational reading frame.
SVs are a broad class of alterations, including inversions, translocations and copy number
alterations (CNAs). CNAs are deleted or amplified regions of the genome wherein a segment of
a chromosome is either deleted (one or both copies) or amplified (more than two copies). CNAs
sometimes, but not always, change the expression level of the proteins encoded in the segment
that is copy number altered. Epigenetic alterations, like changes in DNA methylation or
chromatin packaging, are also important in cancer onset and progression, because they can result
in changes in gene expression levels. For a more detailed description of how different alterations
are detected in sequencing data see section 1.2 and of their importance in cancer genomics see
section 1.3. The work described in this dissertation has primarily focused on improving the
detection of SNVs and INDELs.
A critical challenge in the research and clinical management of cancer is accurately
identifying the genetic alterations that cause the disease and have clinical value, such as
therapeutic response or resistance, or are of prognostic or diagnostic significance. Somatic
alterations are unique to the tumor and are not present in normal tissues. In practice, somatic
alterations are typically identified by obtaining tissue samples of the tumor and a patientmatched, non-malignant tissue normal, isolating DNA from each and sequencing genomic
regions of interest for each tissue isolate. Here, the regions of interest are defined by the study
2

and can include a panel of known cancer genes, all coding gene sequences (the “exome”) or the
entire genome. Current methods to explore cancer genomics utilize MPS instruments and a
variety of preparatory methods that are specific to the type of study being performed. MPS
instruments typically produce short read lengths of DNA sequence from in situ amplified library
fragments. The resulting read data from tumor and normal libraries are aligned separately to the
human genome reference sequence and the read coverage depth is evaluated. Statistical
algorithms compare genomic alterations identified from the tumor data alignments to those
identified from the normal data alignments to ‘call’ putative somatic alterations. The use of MPS
has revolutionized the field of cancer genomics by facilitating the sequencing of entire cancer
and normal genomes as opposed to the use of Sanger sequencing of PCR-targeted genes or loci.
However, there are challenges to the use of MPS methods in cancer research and
diagnostics that lead to difficulties in properly interpreting MPS data from cancer samples. Some
difficulties include inadequate amounts of tumor tissue available for MPS studies, inaccuracies
in the identification of somatic alterations, and the time investment required to carefully interpret
the results, especially in the setting of clinical diagnostics. In this dissertation work, these
limitations were addressed by improving somatic analysis pipelines to (1) better identify
literature-supported clinically and/or biologically important mutations and (2) become more
standardized and automated through the removal of manual analyses. As a result, this work will
improve the accuracy and efficiency of MPS data in clinical cancer diagnostics.

1.2 Overview of Massively Parallel Sequencing
The introduction of dideoxynucleotide chain termination DNA sequencing by Dr. Frederick
Sanger in 1977, coupled with the concepts of molecular cloning from the 1980s, enabled
development of the scientific discipline of genomics. These concepts permitted the decoding of
3

several model organism genomes and culminated with sequencing the Human Reference
Genome in 20043. Shortly after the completion of the Human Reference Genome, the emergence
of several MPS technologies brought about another revolution that eventually led to the use of
MPS in clinical cancer diagnostics4,5. MPS methods dramatically reduced sequencing costs in
comparison to Sanger sequencing by performing sequencing reactions in a ‘massively parallel’
way which, for most technologies, compromised sequencing read lengths in exchange for greater
throughput6. While several MPS sequencing technologies are available in the market, Illumina’s
technology has obtained dominant market share due to its superior accuracy, sequencing
throughput, low cost, and versatility of applications (i.e. whole genome, exome, RNA
sequencing, etc.)7.
While MPS methods have made the production of DNA sequencing data cheaper and
faster, they have made the computational analysis of sequence data more difficult and expensive.
This is due to the greater quantities of data produced, to the complexities of data analysis and to
the need to align short-read sequences as a first step to analysis. Correct read alignment of short
sequence reads is compute-intensive, especially considering the size and repetitive nature of the
human genome. While analysis strategies have, for the most part, kept pace with MPS
technologies, cancer variant identification are still in need of method optimization8.

1.2.1 Illumina Sequencing Technology and Sources of Sequencing Error
Overview of the Illumina sequencing technology
Illumina sequencing technology comprises three main steps: 1) DNA fragmentation, 2) library
construction, and 3) sequencing (on the Illumina sequencing instrument). For example, to
sequence the entire human genome, genomic DNA is isolated and amplified (if necessary). Then,
the high molecular weight DNA is fragmented physically (via sonication or shearing) and size
selected by agarose gel or magnetic bead sizing. Next, in the library construction step, end repair
4

and A-tailing are followed by the ligation of platform-specific adapters to the size selected DNA
fragments. The resulting whole genome sequencing (WGS) library can then be quantified (by
qPCR or a fluorimeter) and diluted to Illumina’s specifications to ensure the proper library
concentration is loaded onto the sequencing instrument, for optimized data yield per instrument
run9.
Optionally, since only 1.5% of the human genome encodes proteins (the “exome), it is
often more cost effective from a sequence data generation and analysis standpoint to sequence
the exome (all coding genes) or a panel of selected genes or regions. This selection of specific
regions from a whole genome library is accomplished by “hybridization capture” using synthetic
probes that select for the genomic DNA targets based on shared sequence similarity. These
probes are either DNA or RNA and contain derivatized biotin molecules so the resulting hybrid
molecules composed of probe and complementary DNA fragment can be isolated from solution
by complexing with streptavidin-coated magnetic beads. Applying a magnetic field to the hybrid
capture magnetic bead mixture permits selective pull-down of the regions of interest. The
resulting library fragments are amplified by a second PCR step and quantitated/diluted prior to
Illumina sequencing.
Illumina MPS occurs in 3 steps: A) cluster generation, B) sequencing by synthesis (SBS),
C) paired end sequencing (optional). Cluster generation occurs on the surface of the Illumina
flow cell which has a lawn of covalently attached adapters across its surface, each of which is
complementary to one of the Illumina specific adapters used in library construction. Due to
complementarity, the library fragments hybridize to the flow cell surface and are then amplified
on the flow cell surface using an isothermal bridge amplification process that is timed to produce
a sufficient fragment density for each cluster. This density of fragments, in turn, permits the
5

instrument’s optics to detect the subsequent SBS reactions. One end of the fragment is released
by a chemical cleavage step that releases one end of each of the fragments in each cluster, and
permits the detached strands to be washed away under denaturing conditions. Following this
step, a sequencing primer is introduced and anneals to the single strands in each cluster,
permitting SBS. Sequencing by synthesis is initiated with the addition of DNA polymerase and a
mixture of custom nucleotides, each with unique fluorescent labels attached to identify the
corresponding nucleotide (A, C, G, or T) and with a 3’-OH blocking group that prevents chain
extension once it is incorporated into the synthesized strand. Following the nucleotide
incorporation step, the clusters are read by determining the emission wavelength of each cluster
after scanning the flow cell surfaces by a laser. Once the instrument’s optics scan both upper and
lower flow cell surfaces to detect which nucleotide was added to each cluster, the fluorescent
label is cleaved from the nucleotides added in that step, and the 3’-OH blocking group is also
cleaved, permitting the polymerase to continue chain elongation by incorporating the subsequent
nucleotide in the next synthesis step. This process is repeated for 100 to 300 nucleotides
depending on the number of cycles specified (# of cycles=read length). With sequencing
complete on one strand of each library fragment, paired end sequencing can be performed by
first performing a second, shorter bridge amplification cycle, followed by cleavage of the second
adapter from the flow cell strand, which releases the opposite end from the flow cell surface and
makes it available for priming by a unique sequencing primer. The sequencing by synthesis then
is repeated, as above. Paired end reads have an analytical advantage because read pairs can be
matched computationally and then aligned to the human reference genome. Since the
approximate distance between the read pairs is known due to the DNA size selection step prior to
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library construction, read pairs that do not map at the anticipated distance, or map with high
quality onto different chromosomes can be interpreted as identifying a structural variant 10.
Sources of Sequencing Error
Sequencing error is defined as nucleotides misread by the sequencing instrument, an event that
occurs on a per-base basis between 0.01% and 1%11. These errors are a result of a variety of
factors including unavoidable inefficiencies in sequencing chemistry, technical errors due to the
camera system, and interference from neighboring clusters or stray nucleotides. Chemical errors
are a result of the reality that chemical reactions used to produce the reagents are never 100%
efficient and these lead to accumulated noise as the step-wise sequencing reactions progress.
Some examples of this type of error include “dephasing” errors which occur, for example, when
a nucleotide without a proper 3’ -OH blocking group is incorporated, and permits a second
nucleotide to be incorporated due to the absence of the blocking group. Similarly, if the 3’-OH
blocking group is not properly cleaved, elongation by the polymerase is terminated for that cycle,
and the affected fragment(s) will be out of sync with others in the cluster, contributing
background noise to the correctly extended and detected fragments in the cluster. These errors
are called ‘dephasing’ errors because they result in affected library fragments in the cluster to be
out of phase with others. Examples of interference errors, or noise that interferes with the
detection of true signals include: failure of enzymatic cleavage of the fluorescent label after
detection, incorporation of multiple fluorescent labels in the same incorporation cycle, or stray
fluorescent labeled nucleotides near a cluster (not removed during the wash cycle following
incorporation). These errors, while small and inconsequential individually (as they typically
affect one of many reads in a cluster), occur with sufficiently common frequency that eventually,
at higher numbers of sequencing cycles, it is impossible to ascertain the signal of the in phase
read fragments in a cluster from the compromised read fragments. As such, Illumina reads tend
7

to be more error prone toward the end of the sequence read. Accumulated noise rates are what
ultimately determines the maximum read length of an Illumina sequencing instrument.
Downstream computational approaches model this error rate in their identification of sources of
false positivity.

1.2.2 Computational Analysis of Massively Parallel Sequencing Data
Following production of short read sequencing data, the single- or paired-end reads must be
aligned to the human reference genome as the first step in variant detection. Following
alignment, duplicate reads, which have same start and end positions as aligned to the reference
genome, are typically removed and variants are called.
Mapping Illumina Sequencing Reads to the Reference Genome
Aligning a ~100 base pair sequencing read to the 3 billion base pair human genome is a
challenging computational problem. Substantial development in short read alignment software
has provided researchers with many viable solutions 12-14. Alignment algorithms are typically able
to uniquely map only 70-80% of reads produced to the reference genome due to a high rate of
homologous or repetitive sequences in the reference genome15. The number of uniquely mapped
reads has increased as Illumina read lengths have increased. While there are dozens of alignment
algorithms available, they are implemented with one of two main architectures: hash based
designs (like Novoalign), or Burrows-Wheeler transform (BWT) aligners (like BWA16, BWAmem17, or bowtie218). Hash based aligners use indexes (hashes), which are short ‘seeds’ of the
reference genome, to identify where portions of the read occur in the genome, and thereafter
these alignments are presented to a local alignment algorithm, like Smith-Waterman19 or
Needleman Wunsch20, where the maximum number of contiguous seeds from the reference
match the read. The local alignment algorithm then produces a high quality alignment (see
Figure 1.1a)14. Hash based aligners tend to be more accurate, but are more computationally
8

intensive and memory inefficient than BWT aligners. BWT aligners concatenate the entire
reference genome into one string, and use a BWT algorithm to store the reference genome in
approximately 2GB of RAM. This approach permits the entire sequence read to be aligned to the
reference genome in a computationally efficient way via a Burrows-Wheeler search followed by
local alignment via Smith-Watterman19. BWT aligners produce an alignment that is extremely
comparable to the alignment accuracy of hash based approaches, yet with substantially improved
computational performance (see Figure 1.1b)14.

Figure 1.1 Comparison of hash based and BWT alignment algorithms. Figure originally published in
Trapnell et. al.14 "(a) Algorithms based on spaced-seed indexing, such as Maq, index the reads as
follows: each position in the reference is cut into equal-sized pieces, called 'seeds' and these seeds are
paired and stored in a lookup table. Each read is also cut up according to this scheme, and pairs of seeds
are used as keys to look up matching positions in the reference. Because seed indices can be very large,
some algorithms (including Maq) index the reads in batches and treat substrings of the reference as
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queries. (b) Algorithms based on the Burrows-Wheeler transform, such as Bowtie, store a memoryefficient representation of the reference genome. Reads are aligned character by character from right to
left against the transformed string. With each new character, the algorithm updates an interval (indicated
by blue 'beams') in the transformed string. When all characters in the read have been processed,
alignments are represented by any positions within the interval. Burrows-Wheeler–based algorithms can
run substantially faster than spaced seed approaches, primarily owing to the memory efficiency of the
Burrows-Wheeler search. Chr., chromosome.” 14

Germline Variant Calling Approaches
DNA sequencing variation is typically called with respect to the reference genome. Specifically,
deviations from the reference sequence are identified and reported as variation. This is
accomplished through different types of variant calling algorithms that use a statistical model to
identify deviations from reference, taking into consideration the known error profile of
sequencing and read alignment. In its simplest form, a variant calling algorithm identifies
positions with one or more reads supporting a non-reference base. It then performs a statistical
test to determine whether the number of reads supporting the putative variant could be expected
by chance given the total number of reads, the error rate of the instrument, and other factors. In
general, high-confidence variants will have a higher proportion of variant reads compared to the
total coverage at the locus. This proportion (variant supporting reads over the total read
coverage) is often referred to as variant allele fraction (or frequency VAF) and is one of several
important metrics used by variant calling algorithms, filtering steps, and in the process of manual
review (see Figure 1.2 for an illustration of the VAF concept). In the germline context, these
variants should occur at 50% (heterozygous) or 100% (homozygous) VAF. In the somatic
context, variants may occur at a variety of VAF percentages, as determined by numerous factors
including their prevalence in the tumor cell population, and overall, by the percentage of tumor
cells present in the piece of tumor used for DNA isolation prior to sequencing. There are variant
callers that are specifically designed for a single type of genetic alteration (SNVs, INDELs, SVs)
and others that are designed to call multiple types of variation. The following section outlines
10

representative examples of callers for each variant type. (for more information on how somatic
alterations are identified in tumor samples see section 1.4)
Many different SNV callers are available. Some widely used germline SNV callers
include GATK21, VarScan22, FreeBayes23, Platypus24, and SAMTools25 (some of these callers
also are able to call somatic variants with matched tumor-normal aligned sequence data inputs;
see subsection 1.4.2). Many SNV callers also identify INDELs including FreeBayes23,
VarScan22, and Platypus24, however, there are INDEL-specific callers that perform more
advanced techniques like local re-alignment around INDELs to improve the accuracy of
identification (GATK21, SAMTools25). This type of specialized treatment is needed because
INDELs are very difficult to uniquely identify and report. This is true because gapped
alignments are generally more challenging to produce and because the same event can be
represented in multiple ways by read alignments, especially as these events increase in length or
occur around repetitive sequences.
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Figure 1.2 Illustration of VAF in MPS sequencing data. This screenshot of the integrative genomics
viewer (IGV)26,27 gives a visual representation of MPS data. The histogram near the top of the screen
illustrates the sequencing coverage at each position. The reads are visualized in the middle of the screen
with the red and blue reads signifying forward and reverse strands, respectively. The green in the reads
illustrate those that contain a variant (A) base. At the variant position, the coverage histogram bars are
colored for the variant (green=’A’) and reference (orange=’G’). The pop up window shows the overall
coverage, the count of each base and the VAF in parentheses (shown as a percentage). VAF is calculated
by dividing the count of variant bases (26) by the total coverage (49).

Since SVs are much more variable in their presentation (event type includes insertions,
deletions, CNVs, inversions, and translocations, all over 50bp), there are a variety of techniques
to identify them, as Alkan et. al. outline in their review28. These computational techniques
include read-pair methods (VariationHunter29-31, BreakDancer32, SPANNER33,34 etc.) that assess
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the span and read orientation of read pairs and perform a clustering step on discordant pairs to
identify SVs. This approach is particularly powerful in detecting insertions, deletions, inversions
and translocations, however, small insert sizes and reads that span the breakpoints are necessary
for fine mapping of the SVs. Additionally, it is very difficult to detect CNVs using read pair
relationships alone because they are primarily focused on the relationship between paired-end
read alignment and not read coverage. Read-depth methods are much better suited to call CNVs
(examples include Breakdancer32, cn.MOPS35, and Tigra-SV36) which model coverage to a
Poisson distribution to identify regions that diverge from the distribution. These methods
generally have poor breakpoint resolution and CNVs are generally hard to call in repetitive
regions or from any capture-based sequencing strategy like exome sequencing because of the
noise introduced by variable/biased hybrid probe capture efficiency37. Split-read methods (like
Pindel38) attempt to identify the breakpoints of SVs by splitting a read and aligning each piece to
the genome. While these approaches can finely map SV breakpoints, short read lengths often
make it difficult to align the splits uniquely to the genome.

1.3 Cancer Genomics Overview
As mentioned in section 1.1, the prevailing strategy for identifying somatic mutations in cancer
is to obtain matched tumor and normal tissue samples from the same individual, perform MPSbased data production, and computationally determine which mutations are unique to the tumor.
This was the prevailing strategy used in the TCGA39 and ICGC40,41 projects, two examples of
large-scale cancer genomics discovery projects that sought to survey the mutational landscape of
human cancers. Somatic mutations can also be inferred when only tumor samples are available
by filtering out presumed germline variation using large scale population databases like 1000
Genomes42, ExAC43, or gnomAD43, although this approach is largely avoided in genomic
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discovery projects. Following identification of somatic mutations, functional impact is predicted
via in silico, in vitro, or in vivo methods, each of which has highly variable cost and throughputs.
Examples of functional prediction include (in order from least costly/time intensive to most): use
of automated algorithms (SIFT44,45, PolyPhen-246, MutationAssessor47, CHASM48, ParsSNP49),
annotation of whether variants are present in other tumor sequencing datasets (COSMIC 50,
TCGA, ICGC), and literature review of variants identified to annotate discovered etiology. More
definitive answers can be pursued by experimental functional strategies using cell lines,
xenografts, or mouse models. Computational procedures are often used to filter and focus
downstream analyses to prioritize interpretation and experimentation. In vitro and in vivo
functional evaluation is generally necessary for full confidence of a mutation’s impact on cancer.

1.3.1 The Genomic Landscape of Human Cancer
Upon completion of the human genome project, there was keen interest in the scientific
community to use this resource and establish sequencing methods to help uncover the mutational
landscape of cancer. The general hypothesis was that the most frequently mutated genes and
amino acid residues (or non-coding positions) were likely to be important in the onset and
progression of the disease. The sequencing of the first complete cancer genome was reported by
Ley et. al. in 200851. In 2009 the U.S. National Cancer Institute launched the Cancer Genome
Atlas (TCGA) project followed soon-after by the creation of the International Cancer Genome
Consortium (ICGC). To date these consortia have sequenced tumors in 21 cancer types from
over 20,000 individuals identifying about 63.5 million somatic mutations
(http://dcc.icgc.org)41,52. Meta-analyses across many of these cancer types has revealed
significant heterogeneity of mutation rates with hematological and pediatric tumors being the
least mutated and tumors from tissue types that are highly exposed to mutagens, such as tobacco
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smoke or ultra violet radiation in lung cancers and melanomas, having the highest mutational
burden (Figure 1.3)53.

Figure 1.3 Mutational heterogeneity of cancer. Figure originally published in Lawrence et. al.53. "Each
dot corresponds to a tumor–normal pair, with vertical position indicating the total frequency of somatic
mutations in the exome. Tumor types are ordered by their median somatic mutation frequency, with the
lowest frequencies (left) found in hematological and pediatric tumors, and the highest (right) in tumors
induced by carcinogens such as tobacco smoke and ultraviolet light. Mutation frequencies vary more than
1,000-fold between lowest and highest across different cancers and also within several tumor types. The
bottom panel shows the relative proportions of the six different possible base-pair substitutions, as
indicated in the legend on the left." 53

1.3.2 Challenges and Error Sources Caused by Cancer Tissues in Genomic
Studies
Since cancers are localized in specific tissues, they are more challenging to obtain or to sample
for genomic sequencing studies, in comparison to germline genetic diseases; where blood, hair,
or saliva samples can be used. Tumor biopsies (or surgical resections) are typically obtained for a
pathologist to evaluate if cells are cancerous by examining their anatomy under a microscope,
often in conjunction with immunohistochemistry. These procedures typically require most of a
limited tissue sample. Additionally, in pathology, it is very common for tumor samples to be
formalin-fixed and paraffin-embedded (FFPE) to preserve the cellular anatomy. Unfortunately,
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this technique can lead to degradation of tumor DNA due to crosslinking of the backbone which
introduces errors that must be accounted for in subsequent analyses 54. Flash freezing of a portion
of the cancer tissue after biopsy or resection in addition to traditional FFPE preservation can be
specified by only when sufficient material is available.
Assuming adequate tumor DNA is obtained for sequencing, cancer biology poses
several additional limitations that impede the accurate detection of somatic mutations in a tumor.
One example is tumor cellularity; it is very rare for a tumor to be composed of 100% cancerous
cells. Rather, normal cells are commonly interspersed with the cancer cells in a tissue sample
such that nucleic acid isolation of the tissue will yield corresponding percentages of tumor and
normal cell genomes. This proportionality can significantly limit the ability to detect somatic
variants when there are more normal cells than tumor, in the worst case making it difficult to
separate variants from the MPS error rate55,56. Additionally, cancer cells are heterogeneous and
constantly evolving, meaning that all cells contain mutations in their genomes that were present
in the founder population of cancer cells, yet may have added new mutations that are not present
in all other tumor cells . This heterogeneity is manifest in the presence of subclonal tumor cell
populations, each with unique mutations and potentially novel drivers 57,58. Because of these and
other factors, there is a great need for methodological developments that improve the sensitivity
and accuracy of somatic variant discovery.

1.4 Somatic Variant Identification and Sources of Error
Accurately identifying the somatic SNVs and INDELs from matched tumor/normal sequencing
data is an immense challenge because of the technical limitations of MPS technologies and the
biological and sampling challenges that lead to reduced variant signal in tumor tissue samples as
discussed above. Ideally, robust user-friendly tools would accept aligned bam files, for tumor
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and normal samples, and output a high-quality list of somatic variants. However, such a tool
must also perform well on a wide variety of cancer types, each with distinct mutational burdens,
varying degrees of tumor cellularity, and clonal architecture. Additionally, the ideal tool must
adapt well to the research budget, i.e. perform as well on lower coverage levels (<50x) as it does
on ultra-deep sequencing(<500x) or on various sequencing assay types including WGS, exome,
and custom capture sequencing. These ‘features’ are desired to overcome the limitations of the
MPS workflow and accurately detect variants. In practice, we see a variety of somatic variant
callers used in the literature with no convergence to any specific caller because each has distinct
strengths and weaknesses. Many studies have compared the performance of various variant
callers and the only consensus is that there is very imperfect to poor concordance between
callers59,60, each exhibits variable performance at different coverage limits61, and performance
varies based on the aligner used62. A primary concern of researchers and clinicians analyzing and
interpreting tumor sequencing data is that they do not miss important functional variants. Thus,
they are often as concerned about false negatives as they are about false positives. A common
analysis strategy is therefore to run multiple variant callers, combine their results via
intersections or unions and filter out the false positives 61,63. In the following section,
representative variant calling error profiles observed in MPS data, somatic variant calling
algorithms, false positive filtering strategies, and validation strategies will be introduced and
explained.

1.4.1 Sources of Error in Variant Calling
Errors that lead to downstream false positive (and false negative) somatic variant calls can be
caused by a variety of factors at each phase of the sequencing workflow, including sample
preparation (e.g. low DNA yield, DNA degradation, sample swaps), library preparation (e.g.
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PCR substitution errors, barcode errors), and sequencing and imaging errors (e.g. cluster
crosstalk, cluster dephasing)64. In addition to processing-related errors, there are several sources
of variant calling errors due to: low variant read data support, low quality variant calling due to
noise, mapping errors to low complexity regions, and others.
Low Variant Read Data Support
Confidence that a putative variant signal is real is the result of observing sufficient numbers of
variant- supporting reads, given coverage at the locus, that means it is highly unlikely that the
observed variant is due to random noise, improper read alignment, and/or analysis-related errors.
As mentioned above, this situation occurs when the tumor cell percentage of the isolated sample
is low, or if the variant is present in a minor subclonal population of cells in the tumor mass.
Both situations can be addressed by sequencing tumors at higher depths, and by the development
of variant callers designed to detect variants at lower VAFs65,66. However, as coverage depth
increases and variant signal decreases, per-base error rates of Illumina sequencing remain the
same, which can diminish the power to confidently call such low VAF variants at extraordinarily
high depths of coverage. As such, accurately separating variant signal from random sequencing
error may require using complicated variant filtering combined with manual review to make
sensitive calls with accuracy. Intricate sequencing strategies, like error corrected sequencing,
exist that directly address this limitation by barcoding unique DNA fragments prior to library
construction and sequencing55,56. The development of computational approaches to improve the
detection of low VAF variants have also been beneficial as they can be incorporated more easily
into existing cancer genomics analytical workflows (see Chapter 3 & 4).
Somatic Variant Interference
A variety of noise sources in the sequencing process can impact the detection of true variant
signals including sequencing errors and sample contamination. While sequencing errors occur at
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a low rate, errors can accumulate at very high depth coverage and thereby are detected as true
variants based on depth of variant-containing reads, as discussed above. Additionally, due to
accumulated sources of noise in Illumina’s technology, sequencing errors occur more commonly
at the ends of sequencing reads. Similarly, there are reads that have a higher mismatch rate, due
to low complexity repeats, and if many such reads pile up at a locus, a somatic variant could be
called. Alternatively, sequencing errors can occur because of enzymatic substitution errors
during PCR amplification steps, particularly in samples with low DNA input, which require
more PCR amplification.
Another problem with low input samples is caused by PCR ‘jackpotting’, wherein
smaller fragments are preferentially amplified and the overall rate of duplication is significantly
elevated. Absent correction, jackpotting can result in erroneous variant calls but computational
de-duplication, found in tools like SAMTools25 or SAMBLASTER67, can help alleviate PCR
jackpotting by removing all but one read of the duplicated read set as defined by shared start and
stop points in the genome alignment. However, reads with the same start and end location, are
still observed occasionally in manual review of variant calls, even after computational deduplication has been performed.
Sample contamination is another source of somatic variant caller interference.
Contamination can occur in a variety of ways, but tends to predominate in preparatory steps,
especially when performed manually instead of by robotic preparation. Here, a trace amount of
contaminating DNA in a library can provide reads that invite variant calls in somatic pipelines.
Additionally, the biology of hematological malignancies, as discussed in subsection 1.3.1, opens
up the possibility for tumor contamination of the normal sample (circulating tumor cells found in
the capillaries of the skin sample that often is used as normal tissue). This type of contamination
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also should be taken into account in somatic variant detection as this is a significant source of
false negative calls.
Multiplexing of samples into sequencing lanes also is a source of sample contamination
that can interfere with somatic variant calling. For example, as Illumina introduces higher
throughput instruments, it has become common to add DNA barcode identifiers (indices) onto
the adaptors used in library construction, and then to pool multiple samples into a single
sequencing lane on the flow cell. Once the sequencing is completed, samples with the same
barcodes can be grouped computationally and aligned to the reference genome. However,
Illumina instruments that use the new ExAmp chemistry, found on the HiSeq X ten/3000/4000
and Novaseq platforms, suffer from index switching on up to 5-10% of sequencing reads on
multiplexed samples68. This process occurs because of low levels of free primers that in
conjunction with ExAmp reagents, results in spurious extension of the library with reads that
have the wrong index, and is especially problematic when single or dual combinatorial indexing
schemes are used69. Index switching at the level of even 1% per lane per flow cell with multiple
samples can introduce interfering reads from common SNPs of unrelated individuals.
Downstream, these errors manifest exactly like a low-level sample contamination issue
originating from preparatory steps as described above, and can lead to putative somatic variants
(low VAF) that are false-positives. Although such contamination can be identified
computationally by performing extra filtering against databases of known SNPs like ExAC or
gNOMAD43, this filtering may miss rare variants. Alternatively, adding unique dual same-same
indexes can completely correct for sample barcode switching 69.
Low Complexity Regions and Mapping Errors
As mentioned earlier, the repetitive nature of the human genome causes specific problems in
proper mapping of short reads to the reference genome that impact somatic variant calling,
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specifically in low complexity and homologous regions. This is principally due to the fact that
many such regions are larger than either the sequence read or the insert size of the library
fragment. Approximately 48% of the human reference is composed of repeats (when considering
all types) that are longer than a typical Illumina read (100bp)15. Li et al found that the error rate
of raw calls of SNVs and INDELs is as high as 1 in 10-15kb, with most errors resulting from low
complexity regions and the incomplete reference genome70. Similarly, highly homologous
regions of the genome exist for many pseudogenes, gene families, or segmental duplication
regions. As a result, a number of sequence reads fail to align or align ambiguously to multiple
positions in the genome. General purpose alignment algorithms will randomly place reads that
map equally to multiple loci, resulting in a putative variant arising from several mis-mapped
reads at the wrong locus.
Other Sources of Variant Calling Errors
Some additional examples of signatures that have been associated with false positive variant
calls are strand bias and short inserts. Strand bias describes a signature where the forward strands
of the sequencing read produce a different result than the reverse strands, or vice-versa71. Short
inserts occur when a DNA fragment with an insert size less that 2 times the length of a
sequencing read is sequenced. This results in the forward and the reverse strand overlapping one
another, and causes problems when there are discrepancies between the two read directions, by
artificially inflating variant counts and VAFs due to false positive variant calls.
While this subsection outlines numerous variant calling error profiles, it is not
comprehensive because new technologies and protocols introduce new sources of error.
Although great care is taken in post-variant calling analysis to remove as many false positives as
possible, without sacrificing false negatives, these sources of error persist.
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1.4.2 Current Practices in Somatic Variant Calling
Somatic variant callers use at least two primary statistical methods to calculate a probabilistic
estimate of a variant being somatic; 1) Bayesian classification (e.g. Strelka 65, MuTect66, and
SomaticSniper72) and 2) simple categorical statistics such as Fisher’s Exact Test (e.g. Varscan273
or Shimmer74). This subsection will present the approaches by which these callers make their
classification, their strengths and weaknesses, and opportunities to improve upon their methods.
All Bayesian variant callers are similar in their use of Bayesian mathematics to compute
the probability that a candidate variant is somatic. This is accomplished by encoding known
genomic features (such as the expected somatic mutation rate of a cancer, the error rate of
sequencing instruments, or the expected VAF of germline variants) into probabilistic priors.
These are then interpreted in conjunction with sequencing data features obtained from an aligned
tumor and normal, such as the count of variant/reference reads (and other important metrics like
base qualities) at each variant position. After candidate variant site probabilities are calculated,
heuristic false positive filters are often used to increase sensitivity and specificity (Table 1.1).
In practice, different callers accomplished this approach differently. For example,
MuTect uses a Bayesian Classifier to identify putative variants in tumor and normal samples
independently, performs false positive filtering, and then utilizes another Bayesian Classifier to
calculate which calls are somatic, germline, or ‘variants’ (insufficient evidence in the normal
sample to call the variant somatic). By contrast, SomaticSniper and Strelka use a Bayesian
Classifier followed by false positive filtering. Additionally, SomaticSniper assumes that variants
will present as heterozygous (~50% VAF) or homozygous (~100% VAF), which is rare for
somatic variants in tumor samples because of clonal diversity and sample purity. The strict
assumptions of homo- and heterozygous VAF substantially limit Somatic Snipers ability to call
low VAF somatic variants. Conversely, Strelka and MuTect make the simplifying assumption
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that the tumor VAF observed is equal to the tumor cell fraction of the sample (in other words, the
sample has perfect representation of tumor cellularity and clonality and the VAF observed is
equal to the proportion of cancer cells with those variants in the sample). While this is an oversimplification, both methods have more statistical power to detect lower VAF somatic variants
because they correct for the heterogeneity or sample purity that does not generalize well to
traditional heterozygous or homozygous models. All of these algorithms utilize prior knowledge
about mutational load in cancer to prevent calling more somatic mutations than one would expect
by chance. However, this can be problematic because of the vast differences in mutational load
in different cancer types. While these callers each have parameters that can be modified to
appropriately adjust for mutational burden, in practice these priors are not commonly updated in
a disease specific manner, and often are not known in advance.
Fisher’s Exact Test (FET) somatic variant callers use FET to statistically model if the
observed counts of variant and reference reads are significantly different between the tumor and
normal sample. In practice this is implemented quite differently in Varscan2 and Shimmer.
Varscan2 uses heuristics to identify candidate variant sites, such as minimum coverage of 3x,
PHRED base quality >20, and VAF >= 8%. Once candidate sites are identified in the tumor and
normal sample independently, sites that occur in the tumor sample but not in the normal are fed
into an FET for somatic evaluation. Sites that occur in the tumor and the normal sample are
evaluated via FET designed for germline evaluation. The somatic FET compares the counts for
reference and variant reads from the tumor and the normal samples and identifies tumor variants
that are statistically significant by virtue of having more variant read support than does the
normal sample. Those sites that are not statistically significant are evaluated by the germline
FET for variant status. The germline FET compares the count of reference and variant reads from
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the normal sample to the null hypothesis of the expected error profile of the sequencing
instrument for a given coverage level, i.e. with 1000x coverage and a 0.001 error rate, one would
expect 1 read to be a sequencing error and 999 to be reference sequence. In Varscan2 this entire
process is followed by false positive filtering. Shimmer is a much simpler workflow, performing
an FET on any candidate variant that has more variant read support than an arbitrary threshold.
The FET tests a null hypothesis that variant reads are randomly distributed between the tumor
and normal sample. It also differs from Varscan2 through the utilization of multiple test
correction to ensure that false positives are not called due to the substantial number of tests
performed in somatic variant detection.
Both Bayesian classifier and FET based algorithms rely heavily on filtering to remove
false positives and improve sensitivity and specificity (MuTect, Strelka, Somatic Sniper, and
Varscan2). However, these filters are often identified empirically and set as heuristics. Different
thresholds can wildly influence the performance of each caller. Additionally, there is no
consensus, between the different methods, on which filters should be used. Of the 4 callers that
utilize false positive filtering, 16 features were listed in the publications for these somatic callers.
Of these, no features were used by all 4 callers, only 3 features were used by 3 callers, 5 features
were used by two callers, and 8 features were used by only one caller (Table 1.1). As a result,
there is significant room for improvement and standardization in the development of high
quality, automated false positive filtering and prediction for somatic variants (see Chapter 4).
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False Positive Filter
Mismatches in variant
reads

Description
A high number of mismatches in a variant read
can be indicative of a mapping error

Variant repetitive regions

MPS technologies perform more poorly in low
complexity regions, including repetitive and
homopolymer runs, of the genome
Mapping quality scores for variant reads are low

Poor mapping quality
Low base quality in
variant read or read
pileup
Strand bias

Observed in normal
Tri-allelic site

Low base qualities across the variant reads,
signifying a sequencing error of the read, or
across all the reads in the locus.
All variant supporting reads are oriented in the
same direction
Variants positioned near the end of the read are
more likely to be artefactual
INDEL in vicinity of variant read. These variants
are likely alignment errors and are a result of the
INDEL not an independent substitution.
Number of variant reads above a defined
threshold
Unusually high coverage in the normal sample
Variant called in both overlapping paired-end
variant reads
Variant support in the normal sample
Multiple variants in the same site

Presence in panel of
normals
Minimum VAF
Distance to 3’ end
Distance to clipped reads

Panel of germline mutations observed in normal
samples.
VAF above a defined threshold.
Variant distance to 3’ end of read fragment
Distance to soft-clipped reads

Average variant read
position
Proximal gap to variant
Minimum variant support
High normal coverage
Short insert

Callers
Strelka,
Somatic sniper,
Varscan2
Strelka,
MuTect,
Varscan2
MuTect,
Somatic sniper,
Varscan2
Strelka,
Somatic sniper
MuTect,
Varscan2
MuTect,
Varscan2
MuTect,
Somatic sniper
Somatic sniper,
Varscan2
Strelka
Strelka
MuTect
MuTect
MuTect
Varscan2
Varscan2
Varscan2

Table 1.1 False positive filtering strategies used in somatic variant callers. Many somatic variant
callers use heuristic false positive filters to increase accuracy. These values can be modified by the user
at runtime to tune performance.

1.4.3 Post-processing of Somatic Variant Calls
Because the different somatic callers have substantially different performance in different
situations (e.g. MuTect is better at detecting low VAF mutations) it is common practice for
somatic calling pipelines to run multiple callers and union (concatenate the calls from each
caller) together to get a highly sensitive candidate somatic variant list. This list will typically
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then undergo extensive false positive filtering, manual review via integrated genomic
viewer(IGV)75, and validation sequencing61. By following this workflow, the entire variant
calling pipeline undergoes project-, and sample-specific post-processing where the relevant
disease biology and sample details are carefully considered when setting thresholds for various
heuristics. Often due to budget constraints, extremely stringent filtering is used to winnow
candidate variants down to a manageable number for the costly and time consuming manual
review and validation steps.
Manual review typically occurs on the filtered candidate call list via visualization of the
raw MPS sequence alignments through a genomic visualization tool like IGV 26. Human
reviewers can readily recognize patterns that are missed by variant calling and filtering. Manual
reviewers look for error patterns like those described in Table 1.1, that were missed in the
filtering of the somatic caller. Such errors occur when certain types of filtering are omitted (note
the lack of overlap between filters in Table 1.1), when multiple of these error features occur in
the same site, or when a variant does not surpass the arbitrary threshold for a given feature, but is
nevertheless plainly obvious to the human eye. For standard procedures on how manual review is
performed on somatic variants as well as illustrative examples of errors, see Appendix 1.
Validation on an orthogonal sequencing technology that (ideally) does not exhibit the
same biases as that used for discovery sequencing, is ideal in somatic variant confirmation. The
most relied on technology for validation sequencing remains Sanger sequencing, however, this is
also the most costly and time consuming. Other MPS technologies, like IonTorrent, are also
commonly used in somatic variant validation as they exhibit different error signatures than the
Illumina platform. Remaining on the Illumina platform, but performing targeted custom capture
sequencing to much greater depth is also a cost effective and trusted source for validation
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sequencing. Other methods to consider include digital droplet PCR, which has excellent
sensitivity to detect variants. Validation sequencing is often limited by the availability of the
tissue to perform the experiment and the cost.

1.5 The Interpretation Bottleneck in Cancer Genomics
The MPS workflow in cancer genomics has been streamlined and optimized from DNA isolation
to somatic variant calling such that throughput is enormous. Despite advances in these areas, post
processing and clinical or biological interpretations of somatic variant calls are becoming
increasingly laborious, resulting in massive bottlenecks that impede the widespread adoption of
precision medicine (see Figure 1.4)76.
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Figure 1.4 The interpretation bottleneck of precision medicine. Figure originally published be Good
et. al. 201476 “A typical cancer genomics workflow, from sequence to report, is illustrated. The upstream,
relatively automated steps (shown by their light color here) involve the production of millions of short
sequence reads from a tumor sample; alignment to the reference genome and application of event
detection algorithms; filtering, manual review and validation to identify high-quality events; and
annotation of events and application of functional prediction algorithms. These steps culminate in the
production of dozens to thousands of potential tumor-driving events that must be interpreted by a skilled
analyst and synthesized in a report. Each event must be researched in the context of current literature
(PubMed), drug-gene interaction databases (DGIdb), relevant clinical trials (ClinTrials) and known
clinical actionability from sources such as My Cancer Genome (MCG)… [This] attempt to infer clinical
actionability represents the most severe bottleneck of the process. The analyst must find their way
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through the dark by extensive manual curation before handing off a report for clinical evaluation and
application by medical professionals.” 76

Analysts faced with large sets of variant calls are over-burdened with the need to perform
validation or manual review of variant calls and then provide interpretations for those variant
observations in the context of clinical and biological knowledge. The current standard procedure
is to annotate variants that have been observed in cancer genomic studies and perform literature
review to explain a variant’s impact on cancer. Resources like TCGA39, and ICGC40,41, or
databases like COSMIC50 are very comprehensive and allow for easy annotation against the
know mutational landscape of human cancers. However, resources that ascertain the biological
or clinical importance of a variant in cancer are much more scarce. Examples include the cancer
gene focused database PHIAL54, or databases that outline clinically important variants and their
impact like MyCancerGenome77, or the Gene Drug Knowledge Database78. While these
databases allow users to quickly browse their contents for identified variants, there are no
programmatic application programming interface (APIs) available to allow this information to
annotate variant calls automatically, resulting in a large manual analysis burden. Additionally,
these resources only capture a small part of what is known in the literature. As a result, to find
biological or clinical information about any given somatic variant, time-consuming literature
review often is necessary. When thousands of somatic variants are called in a genomic study, it is
not tractable to perform literature review on every single variant for studied functional
consequences. Significant developments are necessary to develop resources that streamline the
interpretation of somatic variants and improve their detection (see Chapter 2 & 3).
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1.6 Machine Learning Applications to Variant
Identification, Filtering, and Assessment
As discussed in section 1.4, false positive filtering is used extensively in somatic variant calling
pipelines to produce high quality somatic variant lists. Most often these filters are set as
heuristics with cut off thresholds defined by analysis of experimental data. This approach is
limited by the experimental data used to discover thresholds. If the reference set for delineating
variant calling errors was defined with a significantly different cancer type representation,
sample heterogeneity, or analysis/sequencing strategy used, it may be necessary to manually alter
filters for a new study. This increases analysis cost and complexity by requiring implementation
of increasingly sophisticated hierarchical filters (e.g. if feature W is above X, then filter feature
Y by Z). Traditional programming defines rules and procedures that are then used to process data
(an example is the traditional filtering strategy used in somatic calling pipelines where specific
thresholds need to be set for every variable to define heuristic filters). However, divergent from a
traditional programing paradigm, machine learning algorithms allow a computer to automatically
calculate procedures based on labeled training data. Specific to the filtering strategies described
above, a machine learning algorithm utilizes knowledge of which variants are valid or artefactual
(labels or classes) to learn structure in input variables (features, like VAF and base quality
metrics) that will allow the algorithm to make future classification decisions on unseen data.
These types of machine learning methods are often referred to as classification algorithms.
Machine learning algorithms have many advantages. They can learn extremely
complicated nonlinear or hierarchical data structures and allow these structures to be applied to
previously unseen data points. They can be used to automate time consuming tasks with a great
deal of precision, saving a substantial amount of human analysis time. For example, the manual
review of somatic variant calls required approximately 1 hour of analysis time for 70 variants
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reviewed. A machine learning algorithm could potentially reduce this analysis time to
milliseconds (see Chapter 4).
While machine learning technology is incredibly promising, it is not without its pitfalls.
The saying, ‘garbage in, garbage out’ aptly describes machine learning model performance on
noisy, incomplete or biased training datasets. Great care must be taken in assembling, cleaning,
and normalizing datasets in preparation for ‘training’ a machine learning algorithm.
Additionally, it is important to provide a machine learning algorithm with appropriate and
relevant features (variables) in the proper format for accurate decision making. For example, it
should not be assumed that if a machine learning algorithm is given normal read counts, variant
read counts, and sequencing depth that the algorithm will calculate VAF and utilize it in its
decision making. The process of identifying and designing useful features is thus a critical step in
the development of accurate machine learning algorithms for classification. Once training data
are adequately assembled, experimental design steps, such as selection of cross validation
strategy and independent (held out) test data, should be taken to ensure that the machine learning
algorithm is not over-trained or overfit. This section will introduce standard practices for
cleaning training data, engineering features for genomic datasets, evaluating model performance,
avoiding overfitting, and using three common machine learning techniques (logistic regression,
random forest, and deep learning).

1.6.1 Training Data Assembly, Cleaning, and Feature Engineering in Cancer
Genomics
Assembly of high quality training data is often the most time intensive task in a machine learning
project79. This is because data that are used for training of machine learning models are rarely
collected and stored with machine learning in mind. Data typically are stored in various ‘silos’
and need to be aggregated and standardized for the purposes of machine learning. In cancer
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genomics, data are typically organized by case or project. A case is comprised of a single
patient’s DNA sequencing data collected at various times (e.g., at diagnosis, relapse, or after a
treatment regimen) or tissue locations (i.e. primary tumor, normal, metastasis, etc.); a project is a
collection of cases aggregated to answer a particular hypothesis. Independent cases and project
data may exhibit a wide variety of details in terms of how mutations are discovered, formatted,
and stored.
Bioinformatics as a discipline commonly deals with a large number of file formats and
other caveats that must be considered when attempting to aggregate data across projects. For
example, a common first task is ensuring that all genomic coordinates are in the same genome
build. This typically needs to be done at the file level, such that every alignment file (BAM),
variant call file (VCF), and/or manual review file (BED) file is standardized into the same
context, reference genome build and variant coordinate system (i.e., zero-based or one-based).
Once all individual data are standardized they can be aggregated. It is not uncommon for
different projects to use the sequencing data from the same cases (e.g., if two projects focused on
the same tumor type analyzed by the same group include samples sequenced redundantly in a
prior project). However, if this is the case, care must be taken to eliminate duplicated data that
would otherwise confound the machine learning algorithm (and over-estimate performance)
downstream.
Sparsity, or missing data, can also be a problem for machine learning algorithms. In
cancer genomics data aggregation, this can be a result of different tissue samples being
sequenced between studies (tumor/normal, tumor/normal/relapse, tumor/normal/metastasis,
tumor only, etc.), or mutational status (it is unlikely that many different samples will share a high
number of mutations at the same loci). These missing data can be accounted for by making
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simplifying assumptions like treating tumor-normal pairs from different individuals and different
tissues in the same individual as independent samples, imputing missing genotypes from
population data, or aggregating metrics irrespective of genomic location to compare all variants
against each other.
An essential step in machine learning data aggregation is carefully examining the process
seeking to be automated. In the case of somatic variant post-processing, this would require
extracting and manipulating raw data into numerical values that are most likely to correlate with
class labels. This process is referred to as feature engineering and requires a thorough
understanding of the problem domain space. Once all data across projects are aggregated and
normalized, raw sequencing information can be processed for machine learning. Because bam
files are so large, and only a small percentage of the sequence information relates to individual
somatic variants, it may be more efficient to extract only variant-specific metrics from the bam
file for training. This can be done using a number of tools including SAMtools 25 and bamreadcount (https://github.com/genome/bam-readcount). Once all relevant data are extracted they
can be aggregated with other features such as cancer type. These features can then be
manipulated to increase their value to the downstream classifier. For example, the tools listed
above only provide raw counts for variant and reference bases at a specified position; it is
necessary to use the variant read count and locus coverage to calculate the VAF, a highly
valuable and useful metric commonly used by manual reviewers in decision making. Other
examples of feature engineering include calculating the difference in VAF between the tumor
and the normal sample. Some machine learning methods are more capable of performing feature
engineering as a part of their methodology than others (deep learning approaches can perform
very well with little feature engineering beforehand), however, performance can be substantially
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improved by engineering the feature to focus machine learning algorithms on metrics thought (or
known) to be important in classification. While feature engineering is an important step to
achieve better performance, it is also an opportunity for human bias to be introduced into the
algorithm and so great thought and care should be taken in regards to what features are included
in the model and why they might be important.

1.6.2 Model Performance Assessment and Overfitting
Machine learning methods make predictions by creating a mathematical representation (or
equation commonly referred to as a model) representing the problem at hand. The different
methods used (e.g., logistic regression, random forest, deep learning, etc) define the
mathematical structure of the model, although initially the parameters of that model are often
randomly selected. This model, with random parameters, is then assessed for performance using
a predefined error function that can use a variety of metrics for evaluation: examples include
accuracy, F1 score, or receiver operator characteristic (ROC) area under the curve (AUC). Once
baseline performance has been assessed for random parameters, these parameters can be
iteratively changed until the method converges on a minimum error. This approach is known as
gradient descent. Each machine learning algorithm performs this process slightly differently but
the same general architecture of slowly converging on an optimal solution is followed.
The metrics used to assess model performance can be used in training to converge on the
ideal solution, given the data, and/or to evaluate and compare how different machine learning
algorithms perform. The metric used to assess importance can therefore have a significant impact
on model performance because it is the mathematical constraint used to measure model success
and drive convergence. As such, each metric should be thoroughly understood. Accuracy is the
most straightforward measure of model performance and can be defined as the number of correct
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predictions made by the classifier compared to the total number of examples evaluated. The F 1
score is the harmonic average of precision and recall, or in other words, it considers not only the
false positive rate, as does accuracy, but also the false negative rate. This is due to the accuracy
paradox, where accuracy can increase even though an algorithm’s predictive value does not
change (or even decreases)80. The F1 score accounts for this limitation. ROC AUC builds upon
each of these metrics by evaluating how the precision and recall behaves at all decision
boundaries. As the threshold is changed for what is considered a true positive, the classifier’s
false positive rate and true positive rate are assessed. In contrast to accuracy and F1 score, which
only evaluates model performance at one decision boundary. ROC AUC gives a comprehensive
representation of model performance across all decision boundaries.
Preventing overfitting
Overfitting occurs when an algorithm too closely learns the specific structure of a training
dataset, or “memorizes” the training dataset, and does not generalize well to other datasets (see
Figure 1.581). There are two commonly used techniques to protect against overfitting: (1) crossvalidation in training; and (2) testing model performance against independent test datasets.
In a typical cross-validation scheme, a training sample is partitioned into k equally sized
subsamples. These samples are used as a testing set for a model that was trained on each k-1
superset. In this way, each sample is used in a testing set only once, and evaluation of each
trained model only occurs on samples not used to train that model, minimizing the opportunity
for overfitting. Stratified sampling, ensuring that equal distributions of labels are maintained
between the whole dataset and the subsamples, is important to achieve consistent performance on
datasets with an unbalanced distribution of class labels. While test sets are commonly used in
cross-validation schemes, additional confidence in model performance is obtained when results
replicate to completely independent datasets. Ideally, these would be additional datasets
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specifically collected to test the model. However, in practice it is often too costly to collect a
dataset solely for testing. Therefore, the data set is sometimes randomly segmented before
training and a testing dataset is held out and never utilized in training or cross-validation phases.

Figure 1.5 Visualization of over-fit and well-fit models on training and test datasets. The left plot
illustrates example data for a training dataset and the right plot for the test dataset. The orange line
represents a model that is overfit to the training data and is more poorly fit to the test data. The green
line represents the population structure that the accurattley capture the population trend seen in both
traning and test sets. By Skbkekas (Own work) [CC BY 3.0 (http://creativecommons.org/licenses/by/3.0)],
via Wikimedia Commons81.

1.6.3 Supervised Learning to Perform Classification
Logistic Regression
Logistic regression classifiers in their simplest form estimate numerical features to a binary
classification (true or false) by fitting experimental data to a sigmoid function82. This is
illustrated in Figure 1.6, a hypothetical example where a sigmoid function is fitted to data that
show how hours of studying relate to passing an exam83. The sigmoid function estimates the
probability of passing an exam given the hours that an individual has studied.
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Figure 1.6 Illustration of a sigmoid function fitted to a logistic regression classification estimating the
probability that an individual will pass an exam given hours spent studying. The blue line illustrates the
sigmoid function fit to this data. The points at 0 or 1 indicate whether an individual passed or failed an
exam after the specified number of hours studying. By Michaelg2015 (Own work) [CC BY-SA 4.0
(https://creativecommons.org/licenses/by-sa/4.0)], via Wikimedia Commons83

Logistic regression classifiers can be extended beyond binary classification tasks via a
process called one-versus-all classification. This is a classification scheme where each class is
evaluated against all others, or a classifier is produced for each unique class. For example, if we
had a dataset with classes A, B, and C, one-versus-all classification would produce 3 binary
classifiers. The first would treat the A class as truth (1) and B and C classes as false (0), then, the
B class would be true and A/C would be false, etc. Logistic regression can also be applied to
multivariate datasets, data with many features, as opposed to only one feature as shown in
Figure 1.6. For each feature a weight parameter will be learned by the model that, in conjunction
with all the other parameters, allow the estimator to produce accurate predictions given a dataset.
Logistic regression models are useful because they are efficient to train and are easily
interpretable. The coefficients learned by the model for each feature are the odds ratio, which can
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be used to identify the impact of each feature in classification84. Specifically, the further an
individual coefficient is from zero the more important it is in helping the classifier discern
between classes. Logistic regression models are able to fit simple non-linear features, however,
as training data gets more complex (i.e. the more features that are non-linear) it becomes more
difficult for a logistic regression model to fit the data.
Random Forest
A random forest is an ensemble approach that uses decision trees to learn the structure of data
and random bootstrap aggregating to correct for overfitting 85-88. A decision tree is an algorithm
that uses thresholds for every feature to make classifications with a high degree of specificity
(see Figure 1.789).

Figure 1.7 Example decision tree of survival on the Titanic. Each of the features (blue) lead to more
specific feature filtering or survival status (green or red).89

Decision trees can be extremely precise in their learning of data and quick to train, however they
are prone to overfitting especially on deeper trees 90. Random forest corrects this overfitting
problem by taking the averages of trends learned across many trees. This process sacrifices the
innate intuitiveness of decision trees, but substantially improves the performance on unseen data.
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Random bootstrap aggregating has 3 steps. 1) taking random samples of the training data with
replacement (bootstrapping) to produce many trees (a forest). 2) Randomly selecting a subset of
features that will be used to compute the decision boundary for each branch. 3) Assessing
performance of the forest by feeding labeled examples through each tree in the forest and letting
each tree vote for the classification status of the sample. This process is more opaque than how
decision trees make decisions but is still able to calculate feature importance by tallying the
‘votes’ of how often a feature is used in classification. Random forests are powerful because they
can learn mixed numerical and categorical features, can learn complicated non-linear
relationships, and are straightforward to work with. A drawbacks of random forests is that they
take the same amount of time to make predictions as they do to train (input variables must
traverse the entire forest regardless), so they can have comparatively slower prediction times
than other algorithms.
Deep Learning
In recent years, the term deep learning has become synonymous with neural networks, a
subspecialty of machine learning that has existed for decades 91. Neural networks have gone in
and out of favor many times in the decades since their invention in 1957 and have gone by many
names: artificial neural networks, multilayer perceptron, feed forward neural network, deep
learning etc. While there are semantic differences referred to with each term in the field,
colloquially many of these terms are used interchangeably to describe neural computing.
A neural network is a mathematical representation of how we understand the brain to
process information. The brain’s neurons take nerve stimuli, from our body (skin, eyes, ears,
etc.), as inputs to a complex network of neurons. These neurons process these inputs
biochemically and send results to other neurons in an extremely complicated network. While
artificial neural networks are mathematical abstractions of this biological reality, they are not
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nearly as complicated in their network architecture as a brain. In their simplest form,
computational neural networks (NN) are comprised of an input layer, a hidden layer, and an
output layer (Figure 1.8).

Input layer

Hidden layer

Ouput layer

Feature 1

Feature 2

Feature 3

Figure 1.8 Simple illustration of a feed forward neural network.

Each feature feeds into every hidden layer along with a randomly initialized weight variable.
These values are fed through the hidden layer into the output layer. Hence the name feed forward
neural network. What happens at each node is similar mathematically to the logistic regression
algorithm introduced above. The feature values are fed into an activation function, like a sigmoid
function, and they output a value between 0 and 1 that is passed into the output layer or another
hidden layer. A variety of activation functions are common in neural networks including
sigmoid, hyperbolic tangent (tanh), and rectified linear unit (relu). Similar to logistic regression,
these networks are trained using some flavor of gradient descent to converge on a minimum
error. The main difference in NN is that weights need to be updated for every node of every layer
as opposed to updating one function in logistic regression. For this reason, training neural
networks can be extremely costly. Recent improvements in computing speed and the discovery
of techniques like backpropagation have led to a resurgence of NN in recent years because they
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are now utilized on enormous data sizes. Backpropagation, or backward propagation of errors, is
a mathematical technique that allows the errors to be fed back through the network, similar to
how features are fed into the network, and to modify the weights by gradient descent at each and
every node with extreme efficiency92. These advances have also made training deeper networks,
NN with more hidden layers, and other networks with complex architectures (convolutional NN
and recurrent NN) more common (these deeper and complex architectures are commonly called
deep learning). This has ushered in a renaissance of the field as it has allowed computer
intelligence to exceed human performance on tasks like image recognition or even extremely
complex strategy games such as GO93.
While deep learning has led to astounding advances, it has some important weaknesses.
First, it typically takes an extremely large training dataset size for deep learning to outperform
approaches like random forests. This, coupled with the fact that deep learning is extremely
computationally expensive to train can be a deterrent to using this method. Perhaps deep
learning’s biggest weakness is that it acts like a black box. In other words, it is extremely
difficult to determine how and why a deep learning model made the decisions that it did. Despite
these drawbacks, the ability to learn complicated structure makes deep learning an attractive
method to implement for many machine learning tasks. (see Chapter 4)

1.7 Addressing the Somatic Variant Identification and
Interpretation Bottleneck
As described in section 1.5, while substantial progress has been made in the utilization of MPS
data for cancer genomics, substantial bottlenecks are still present that contribute to the difficulty
of making cancer genomic information useful clinically (see Figure 1.4). Open source, openly
licensed and computationally friendly resources are needed to widen the somatic variant
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detection bottleneck76. In Chapter 2, DoCM a database of curated mutation in cancers is
described as a solution to enable crowd sourced curation of variants from the literature that are
clinically and biologically important to cancer. In Chapter 3, the utility of DoCM is demonstrated
by rescuing clinically and biologically important somatic variants from four TCGA project
datasets through targeted manual review and validation sequencing. In Chapter 4, a machine
learning classifier, trained on 41,000 somatic variants from 20 cancer genomics projects, is
presented that automates manual review and false positive filtering. This work will widen the
somatic variant identification bottleneck and streamline and standardize analysis
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Chapter 2: DoCM: a Database of Curated
Mutations in Cancer
Ainscough, B. J. et al. DoCM: a database of curated mutations in cancer. Nat Methods 13, 806807, doi:10.1038/nmeth.4000 (2016)
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2.1 Introduction
Large-scale cancer genomics discovery projects such as The Cancer Genome Atlas (TCGA) and
the International Cancer Genome Consortium (ICGC) have systematically characterized the
molecular lesions in human cancer genomes, thereby laying the foundation for precision cancer
medicine. However, a curated set of somatic variants with established relevance to cancer
biology is essential for clinical annotation and for use in computational data analysis. A variety
of somatic cancer variant databases exist that help identify important variants, including genelevel54, variant-level41,50, and clinically-focused variant interpretation databases77,78,94. These
resources have greatly increased our understanding of the landscape of clinically and biologically
relevant cancer variants, and when used in aggregate provide an understanding of the relevance
of specific variants. We have created a database of curated mutations in cancer (DoCM,
http://docm.info), an open-source, openly licensed resource to enable the cancer research
community to aggregate, store, and track biologically important cancer variants with provenance
supported by the literature.
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2.2 Results
DoCM is a curated repository that facilitates the aggregation of gene and variant information for
variants with prognostic, diagnostic, predictive, or functional roles from these resources as well
as from individually curated publications (Figure 2.1 and Table 2.1).

Figure 2.1 Overview of DoCM resource. (A) Outline of criteria to curate a variant. Variants are
evaluated for inclusion and then curated elements are identified. (B) Summary of current DoCM contents.
DoCM contains SNSs and indels across many cancer subtypes with easy identification of the journal
article that outlines the variant’s relevance. (C) Screenshot of the DoCM web application available at
http://docm.info. (D) Illustration of the API. An HTTP GET request for a variety of parameters including
gene, chromosome, position etc. and returns a JSON response with the PubMed ids, diseases and other
useful information. The API is thoroughly documented at http://docm.genome.wustl.edu/api.
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DoCM Feature

Type

Quantity

Variant types

SNSs

1,302

INDELs

35

DNSs

27

Missense

1,276

Stop

45

Frameshift

18

Inframe

15

Start lost

5

Synonymous

4

Protein

1

Variant effect

Drugs

96

Cancer subtypes

122

Genes (transcripts)

132 (184)

Publications

876

Table 2.1 Summary of DoCM resource contents (v3.2)

DoCM currently houses 1,364 variants in 132 genes across 122 cancer subtypes, based on the
curation of 876 publications (Figure 2.1B and Table 2.1). The variant types currently in DoCM
include SNSs (95.5% of entries), indels (2.6% of entries), and dinucleotide substitutions (DNSs;
2% of entries). To date, the DoCM web application has approximately 24,000 page views and
approximately 8,500 unique users. In aggregate, users have spent hundreds of hours interacting
with the website and include individuals from every continent with the highest traffic coming
from the USA. DoCM’s open-access model has allowed the resource to be useful to the
community, prior to publication, being used in original research95, incorporated into other
resources96,97, and highlighted in a review98.
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Figure 2.2 Screenshot of DoCM batch submission form. In the batch submission form, users can enter
all the parameters necessary for inclusion into DoCM, including the name of the batch, the rationale
statement outlining the reason for including the variants and curation details, any relevant urls, tags to
be applied to the whole batch, the TSV file with variants and submitter information. Following submission
the user will be given a link to review the batch and any messages from moderators.
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Figure 2.3 Screenshot of moderators view of the submitted batches queue. Once a batch has been
submitted, it can be reviewed in the password protected moderator queue. A listing of current DoCM
moderators can be viewed at http://docm.genome.wustl.edu/about. Moderators can select a batch, such as
the Drug Gene Knowledge Database highlighted in purple above, to review the batch. Once multiple
batches have been accepted a moderator can create a new DoCM version using the blue button at the
bottom-right of the screen. The “Drug Gene Knowledge Database” link is highlighted in purple as it is
the subject of Figure 2.4.
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Figure 2.4 Screenshot of moderator review page. A moderator can review all information submitted
with a batch and evaluate whether it fits the scope and quality requirements of DoCM. Individual variants
can be accepted or rejected and the moderator can leave a message to the submitter.
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DoCM's scope and its batch submission process (Figures 2.2-2.4) place it at a critical
intersection between the two major tradeoffs of curated resources: comprehensiveness of variants
and curation burden (Figure 2.5). The automated batch submission and the review system allow
DoCM curations to scale easily.

Figure 2.5 Putting DoCM in the context of other resources. DoCM in the landscape of selected
databases that collect and curate variants.

Curation of the literature to produce a high-quality set of pathogenic somatic variants is
not trivial, on account of the large number of papers and laborious curation process (Figure 2.6).
Hence, we designed DoCM as an open resource that can coordinate contributions from research
and clinical practitioners. Once important variants are identified, curation efforts are required to
format, standardize, and structure the variants for inclusion in DoCM (see section 2.3 and Figure
2.7). A set of such curated variants can be contributed to DoCM by batch submission at
http://docm.info/variant_submission, whereupon it is reviewed and evaluated by DoCM editors

50

for possible inclusion. DoCM is licensed under the creative commons attribution license (CC BY
4.0), allowing academic and industry researchers unencumbered access to the content.

Figure 2.6 Number of papers in PubMed indexed by "Cancer" per year. Searching PubMed with the
search term “Cancer” yields the number of papers relating to cancer per year. This serves as an upperbound limit of the number of papers that need to be curated to accurately summarize important cancer
variants. There is a need for public resources that reduce the duplication of curation effort.
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Figure 2.7 Overview of variant curation for every entry into DoCM. An anecdotal example of the
curation involved for the variant BRAF V600E is shown. Typically, the literature only lists the gene and
amino acid change (purple in the figure), requiring extensive curation to uniquely identify the variant.
Correct genomic coordinates on a consistent genome build need to be identified, with accompanying
nucleotide and strand information. Occasionally there are multiple nucleotide changes that are
synonymous with a particular amino acid change. A representative transcript that correctly models the
variant described in the literature also needs to be specified. Cancer subtypes are specified using the
disease ontology nomenclature. Green boxes note the class of information that needs to be captured in
DoCM, black boxes show the subtype of each class, and white boxes denote the value.
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2.3 Methods
2.3.1 Somatic variant curation
Curation of the literature to produce a high quality set of pathogenic somatic variants is not
trivial. Once identified, these variants require significant curation efforts to format and
standardize the variants in a structured way for storage and retrieval in a relational database. For
example, publications often only specify the amino acid change and gene name to describe the
variant. Hence, for each variant a curator must reconstruct the genomic location, genome
version, relevant transcript, and nucleic acid variant from the manuscript. Even when some of
this information is specified, it is often from an outdated genome reference or transcript
build/version (Figures 2.1A and 2.6).
To be included in DoCM, variants needed to be supported by peer-reviewed literature
and/or by expert opinion indicating their relevance to cancer or a cancer subtype. Relevant
publications were identified by PubMed searches and inspired by other somatic variant
databases, such as CIViC (www.civicdb.org)99, My Cancer Genome77, OncoMap94, and the Gene
Drug Knowledge Database78. We reviewed publications referenced in these resources to
determine the variant’s suitability for inclusion in DoCM. Where licensing permissions allowed,
the underlying metadata from the resource was included in the DoCM knowledgebase; otherwise
a link to the source resource was included for reference.
The criteria for inclusion in DoCM are as follows. Variants, single nucleotide
substitutions (SNSs) and insertions and deletions (indels), must have published evidence of
clinical relevance, such as prognostic or diagnostic information and/or response data for targeted
therapies. For example, a BRAF V600E variant might be considered a clinically important
variant, as melanomas with this variant are sensitive to the drug vemurafenib 100. Additionally,
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variants whose etiology in cancer has been established by functional experimentation, in either
cell lines or model organisms, were included. Lastly, variation that has been observed in large
scale sequencing efforts as being significantly associated with a particular cancer type were
included in the resource (in this category significant recurrence and expert opinion was
preferred).
Variants can be grouped into batches by commonalities like disease or mutation type if
curated directly from the literature. Batches can also be created based on a publically available
listing of variants that is in scope for the DoCM resource, like My Cancer Genome or the Drug
Gene Knowledge Database. Batches can be submitted, following the instructions
(http://docm.genome.wustl.edu/batch_submission_help), on the batch submission page (Figure
2.2)(http://docm.genome.wustl.edu/batches/new). Curators should annotate their curation process
and explain the reasoning for including a batch into DoCM in the batch rationale statement on
the submission form. This statement provides transparency to the curation process and allows
DoCM users to better understand why variants were included.
Variants of sufficient biological or clinical importance were included in DoCM and
annotated with the correct genomic position, nucleic acid change, associated cancer subtype,
transcript, and any relevant tags. The genomic location of any variant was obtained from the
publication, and converted to reference genome build GRCh37. However, publications rarely
specify all relevant information needed to easily identify a particular variant. Often only the gene
and amino acid change were listed (e.g., BRAF V600E); in such cases the genomic location must
be manually determined by referencing resources like the UCSC 101 or IGV26 genome browsers
and appropriate gene annotation tracks such as Ensembl. If there were multiple nucleic acid
variants that could result in the same amino acid change, then they were both included in the
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database. Additionally, a representative transcript that is compatible with the amino acid variant
was also obtained if not specified in the publication.

2.3.2 Batch Submission and review process
Following submission of a batch, the DoCM web app automatically annotates the variants using
VEP102, validates the publication’s pubmed ids using PubMed, and validates the disease ontology
ids using the disease ontology API103. After annotation and validation, the variants are reviewed
by the moderators listed on DoCM’s about page (http://docm.genome.wustl.edu/about). DoCM
moderators ensure that the submitted batch contains no errors in annotation and validation, that
the batch is within the scope of the resource, and that the variants appear to be referenced in the
listed literature. The moderator will start a dialogue with the submitter via email to correct any
errors/discrepancies and then accept or reject the variants in the batch. These variants are then
staged for inclusion in DoCM and upon submission of multiple batches the moderator can create
a new version of the database (Figures 2.3-2.4).

2.3.3 DoCM web application implementation
The DoCM web application was built using Ruby on Rails (>= 1.9.3) with a PostgreSQL (>= 9)
database backend. The application is open source (code available at
https://github.com/genome/docm ) and openly licensed (MIT open source). The application is
organized using a model-view-controller (MVC) architecture. DoCM variants can be browsed
and searched using the web interface, which has both quick search and advanced filtering
functions. Additionally, the web application features a RESTful application programming
interface (API), that allows for easy integration into other computational systems. Additionally,
the API features a versioning system that allows for users to get consistent responses even as the
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resource is updated and new sources are included. The web application also features the option
for direct download of the curated variants in TSV or VCF formats.
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Chapter 3: DoCM Rescues Clinically
Impactful Cancer Mutations
Ainscough, B. J. et al. DoCM: a database of curated mutations in cancer. Nat Methods 13, 806807, doi:10.1038/nmeth.4000 (2016)
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3.1 Abstract
While DoCM has utility for annotating pathogenic variants with relevant publication support, it
can also contribute to the analysis of sequencing data. For example, it is the nature of analytical
pipelines for somatic variant detection that bona fide somatic mutations may be missed due to
various causes–including overly stringent filtering, alignment challenges, low tumor purity,
tumor heterogeneity, tumor contamination of normal, lack of data coverage, and other issues.
This is particularly problematic when a variant with a known biological function or clinical
action, such as those populating DoCM, is not detected. While missing a variant can adversely
impact both research and clinical sequencing, it is particularly pertinent in the clinical assay of
tumor DNA, where a false negative may represent a missed opportunity for more optimal disease
management. To illustrate the utility of DoCM, we performed a focused knowledge-based
variant discovery study to identify pathogenic variants missed in 1,833 cases across four TCGA
projects. Validation sequencing data from 93 of these cases showed that at least one functionally
important variant in DoCM was recovered in 41% of cases.

3.2 Results
3.2.1 DoCM recovers missed somatic variants
While DoCM has utility for annotating pathogenic variants with relevant publication support, it
can also contribute to the analysis of sequencing data. For example, it is the nature of analytical
pipelines for somatic variant detection that bona fide somatic variants may be missed due to
various causes–including overly stringent filtering, alignment challenges, low tumor purity,
tumor heterogeneity, tumor contamination of normal, lack of data coverage, and other issues 61.
This is particularly problematic when a variant with a known biological function or clinical
action, such as those populating DoCM, is not detected. While missing a variant can adversely
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impact both research and clinical sequencing, it is particularly pertinent in the clinical setting,
where a false negative may represent a missed opportunity for more optimal disease
management. Herein we demonstrate the use of DoCM, a knowledgebase of clinically and/or
biologically relevant cancer variants, to recover missed somatic variants in cancer sequencing
data.
As a proof of principle for DoCM’s utility, we designed a method to recover variants
missed through traditional analysis strategies. This method utilizes DoCM to perform
knowledge-driven identification of minimally supported variants followed by manual review and
validation sequencing (MSRV). Here, MSRV identified pathogenic loci with two or more
supporting sequence reads, followed by manual review for errors (Figure 3.1A), and subsequent
validation sequencing (see section 4.3 methods). We applied the DoCM-MSRV variant recovery
method by analyzing all DoCM sites (data freeze; 488 variants) in the sequencing data from four
TCGA projects (Figure 3.1): AML), BRCA, OVCA, and UCEC. DoCM identified 10,174
minimally supported variants that were manually reviewed by an expert genome analyst. Of
these, 1,833 variants passed manual review (i.e. showed sufficient evidence to warrant validation
sequencing). A subset of these putative somatic variants, 1,228 of 1,833 (66.99%), was not
reported by the respective TCGA variant calling pipeline (Figure 3.1B, Table 3.1).
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Figure 3.1 Overview of analysis and validation sequencing of four TCGA projects. (A) Outline of the
manual review strategy. DoCM sites with two or more reads of support are evaluated for obvious errors.
(B) Summary of the variants that passed manual review and were not identified in the original TCGA
analyses. (C) Summary of the variants that were validated in the 93 validation samples. (D) Comparison
of DoCM-MSRV to ClinSek and the Bayesian classifier.
AML

BRCA

OVCA

UCEC

Number of individuals

200

990

415

228

DoCM sites counted across all samples (488 unique
DoCM sites)

95,406 483,120 202,520 140,544

DoCM variant sites with >= 2 reads of support

1,641

4,055

3,239

1,239

DoCM variants called somatic via manual review

339

885

306

303

DoCM variants called somatic after manual review AND
identified in TCGA

130

256

40

180

DoCM variants called somatic after manual review NOT
identified in TCGA

209

629

267

123

Table 3.1 Summary of variants identified in TCGA data through manual review.

We next selected 48 cases (tumor-normal pairs) from the AML and BRCA TCGA
projects, each of which containing one or more of the 1,833 putative variants, and performed
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validation sequencing using a targeted hybrid capture approach on both tumor and normal
samples (see section 4.3 methods). We generated new libraries and used differentially barcoded
indices on either end of the sequencing libraries to limit the likelihood that observed variants
were due to sequencing artifacts via crosstalk from a single end barcode. One BRCA case and
two AML cases failed library construction and QC checks, leaving 93 total cases in our
validation cohort. After sequencing, we achieved a mean coverage of 173-fold at DoCM sites,
and 95.5% of DoCM sites had at least 50-fold coverage (Figure 3.2).

Figure 3.2 Coverage of the custom capture validation sequencing. Heatmap illustrating the coverage
obtained at all target sites in validation sequencing. Bar graphs on the x and y-axes illustrate the mean
coverage at each case/position.

For those cases with validation sequencing data, 253 putative somatic variants were missed in
the original TCGA analysis and passed manual review. Of these, 19% (49) also passed the
validation threshold (5 or more reads supporting the variant) (Table 3.2). Here, DoCM-MSRV
was able to detect variants below 10% variant allele fraction (VAF), many of which are
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approaching the noise level of the sequencing instrument. Assuming a 1% error rate for a
sequencing instrument, one would expect at least one read to contain a sequencing artifact at a
given position with a depth of 100x. Therefore, our decision to review any variant with 2 or more
supporting data reads approaches the detection limits of the sequencing instrument. As a result,
we expected and observed a large false positive rate among DoCM-MSRV-identified putative
variants prior to validation sequencing (~20% of putative variants validated in subsequent
resequencing).
AML
Number of individuals where validation sequencing was performed 46
Putative variants called somatic via manual review 155
Putative somatic variants identified in TCGA 27
Putative somatic variants not identified in TCGA 128
Validated variants (>=5 reads, not called in TCGA, somatic in manual review) 27
Unvalidated variants (<5 reads, not called in TCGA, somatic in manual review) 97
Number of individuals with validated variant rescued 22/46
Table 3.2 Summary of validation sequencing results.

BRCA
47
143
18
125
23
104
16/47

The presence of these validated, rescued variants observed elsewhere in TCGA coupled to the
knowledge that all such variants are important in cancer gives high confidence in the validity of
these variants. DoCM-MSRV was able to rescue variants across a broad range of VAFs (1.4% 91%)( Figure 3.3) and identified at least one biologically important variant in 38 of 93 (41%)
cases (Figure 3.1C, Table 3.2). If we extrapolate the rate of DoCM-MSRV detected variants to
all cases in all four TCGA projects, we estimate that approximately 238 variants would be
rescued. Similarly, we estimate that we would identify approximately 715 (out of 1743) cases
where we would recover at least one or more clinically relevant variants that were missed in the
TCGA pipeline (Table 3.3).
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Figure 3.3 Overview of validation sequencing results. Variant allele fraction plot illustrating the types
of variants identified through manual review that validated. Variants called in the original TCGA study
are highlighted in blue and those missed are in green. Note that TCGA was unable to call variants below
~10% VAF while the MSRV approach was able to recover many such variants. Density plots on the x and
y-axes show the distribution of tumor VAF and coverage depth for validated variants respectively.
Extrapolated estimation AML BRCA OVCA UCEC
Estimated number of variants that would validate 40
122
52
24
Estimated number of samples with rescued variants 84
398
169
94
Table 3.3 Estimated number of variants detected and samples with a recovered variant, extrapolated
using the rate of recovery, in the validation data

3.2.2 Variant calling of validation sequencing data and comparison to MSRV
We performed orthogonal variant calling on the validation sequencing data using ClinSek104 to
compare how DoCM-MSRV performed against a knowledge-driven statistical approach. ClinSek
identified 29 total somatic variants from the AML (13 variants) and BRCA (16 variants)
validation cases, all of which were identified via the DoCM-MSRV approach (Figure 3.1C). The
majority of variants that ClinSek missed (14/20) were AML cases with evidence of tumor
contamination of the normal. In a second comparison, we evaluated all sites using a Bayesian
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classifier with a binomial log likelihood ratio filter (LLR > 10) to identify somatic sites (see
section 4.3 methods). The filter identified 18/49 variants found through DoCM-MSRV; no
additional variants were identified (Figure 3.1C). Of the 31 variants missed by the Bayesian
classifier, 21 were likely not identified due to low VAFs (mean tumor VAF: 18%, st. dev.: 27%)
and the remaining 10 variants (all from AML samples) showed evidence of tumor contamination
of the normal upon manual review. In summary, 10 variants were called by all three methods and
29 were called by at least two methods (Figure 3.1D).

3.2.3 Cost benefit analysis of DoCM-MSRV approach
Performing the manual review portion of the DoCM-MSRV approach is not very costly. Using
our cutoffs for this experiment (488 variants per sample counted, those with 2 or more reads of
support were manually reviewed) there were 5.5 variants on average needing review. That cost
us an average of $2.37 per case across all 1,833 cases evaluated. Given that these putative
variants have established importance in the literature, this is a small price to pay to ensure that
important variants are not missed. Validation sequencing is much more costly; sequencing 96
cases cost on average $322.01 per case. It is worth noting that sequencing costs could be reduced
in a production assay, as we designed and purchased hybrid capture probes for this experiment
that can be reused on many samples afterwards. Additionally, the targeted capture sequencing
methodology could be greatly optimized for cost if performed at scale and it would not be
necessary to assess all 488 sites as we did, merely the putative somatic sites could be assayed.
While the DoCM-MSRV method proved to have the best sensitivity, computational approaches
like ClinSek and the bayesian classifier had excellent specificity and could identify a majority of
the important variants at little cost.
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3.2.4 Clinically actionable variants rescued by DoCM-MSRV
Using this knowledge-driven approach we were able to rescue missed variants with likely
clinical impact, even in the relatively small sample set for which we performed validation
sequencing (n=93). For example, FLT3 variants (D835E/N/Y and N676K) were identified in
three AML cases (TCGA-AB-2835, TCGA-AB-2919, and TCGA-AB-2922). These variants are
potentially sensitive to targeted therapies like sunitinib105,106. We also identified two AML cases
with KIT N822K variants for which cell line studies indicate sensitivity to dasatinib 107. We
identified 13 BRCA cases that harbored variants in PIK3CA (E542K, E545K, and H1047R) or
PTEN (R130Q) suggesting sensitivity to PI3-kinase pathway inhibitors108,109. Of the variants we
validated, the mean VAF was 25.5% with a standard deviation of 23%, indicating that most
validated sites were at low VAF (Figure 3.3) and are likely the result of sub-clonality or low
tumor purity. Hence, DoCM can provide a vitally important capability to detect challenging
variants that are in some cases potential harbingers of acquired resistance.
The identification of variants of biological import is particularly germane to clinical
sequencing workflows, which are rapidly being established in clinical cancer care, since a false
negative result would miss an important clinical indicator. In the research setting, DoCM has
proven valuable in identifying previously undiscovered variants of potential clinical importance
that were completely missed by large-scale discovery efforts such as TCGA. As our
understanding of the functional landscape of cancer variants grows, and as that information is
curated in DoCM, this knowledge-based variant detection strategy will become increasingly
valuable.
The DoCM-MSRV method demonstrated that clinically relevant somatic variants are
often missed. Hence, including the DoCM-MSRV approach as a failsafe in clinical analysis
pipelines can ensure the likelihood of false negatives in a clinical assay is very low. In a
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comparison to other methods, DoCM-MSRV rescued the largest number of known pathogenic
variants due to its sensitivity to variants at low VAF or with contaminating tumor signatures in
the “normal” comparator specimen. Other highly sensitive variant calling methods have been
developed since these earlier TCGA analyses were performed 65,66. However, without a
knowledge-based filter, these algorithms have substantially higher false negative rates of variant
detection when compared to DoCM-MSRV.

3.3 Methods
3.3.1 Recovery of unidentified DoCM variation in the TCGA data using
manual review and validation sequencing (MSRV)
Important somatic variants are sometimes missed by variant calling pipelines. To illustrate the
utility of DoCM we applied the knowledge-base to our cancer genomics pipeline 110. We used
data from four TCGA projects: Acute Myeloid Leukemia (AML), Breast Cancer (BRCA),
Ovarian Carcinoma (OVCA), and Uterine Corpus Endometrial Carcinoma (UCEC)111-114. All
publically available samples were used. These projects were chosen because of the availability of
their data and our access to a subset of the samples allowing us to perform validation. The TCGA
exomes are available via the database of genotypes and phenotypes (dbGaP) study accession
number phs000178.v9.p8.
We developed an approach for manual review and validation sequencing that first
involved obtaining variant and reference base supporting read counts for all variants in DoCM
using bam-readcount (https://github.com/genome/bam-readcount). Any variant with more than 2
reads of support was sent to an expert for manual review, a process that we typically perform on
variants called by somatic variant callers to eliminate false positives. After manual review, we
performed a validation sequencing experiment using targeted capture probes for all DoCM sites
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in 46 AML and 47 BRCA individuals. Samples with the highest number of putative somatic
variant calls were chosen for validation sequencing. For any given individual, this filtering
strategy lead to 5-20 variants to review.

3.3.2 Manual Review
Manual review involves inspecting raw sequence data (alignments) to correctly identify real
somatic variants and likely sequencing/mapping artifacts using a genome viewer such as IGV 27.
A reviewer examined the bam files for tumor and matched normal samples concurrently and
interrogated the data for a variety of causes of error. These errors can be due to sequencing or
alignment errors, such as those found at highly repetitive or GC-rich regions of the genome. A
reviewer will also look for inflated support for a somatic variant. For example, if a variant with
10 reads supporting a variant in the tumor sample is being evaluated, but 7 of those reads contain
multiple discrepancies at other positions on the read (indicating misaligned reads), only three
believable reads support this somatic variant at the locus and it is much less likely to be a real
variant. In blood cancers in particular, there is often tumor cell contamination of the matched
normal sample (e.g., skin) that leads to higher than usual levels of tumor variant signal in the
normal data. This can result in false negatives as many somatic variant callers have a strong
assumption that a variant will not be present in the normal above the rate expected by random
sequencing errors. Also, the clonal heterogeneity of cancer can cause variants from a smaller
sub-clone to not have sufficient signal to be identified by a somatic variant caller, however a
reviewer can identify a trend of low variant allele fraction (VAF) variants with consistent levels
throughout the sample suggesting that they are real. Low VAF can also be caused by low tumor
cellularity.
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In this study, we established a baseline for missed important variations, ensuring the
utmost sensitivity for clinically impactful variant detection. As such, we gave our reviewers
special instructions to pass any variants that they believed were worth attempting to validate via
custom capture sequencing.

3.3.3 Manual review guidelines
Manual Review Tab Delimited Reports:
Format:
Chromosome Start Stop Reference Variant Called Code Description Code
1

50000 50000 A

C

A

LV,SI

Called/Description Codes should all be uppercase
Only 1 Called Code allowed
Multiple Descriptions Codes allowed and should be comma separated with no spaces in
between

Called Code:
Code Description
A

Ambiguous, variant could or could not be real

F

Fail, variant failed manual review

G

Germline, variant is a real germline variant

S

Somatic, variant is a real somatic variant

Description Codes:
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Code Description
AI

Adjacent Indel, Variant likely due to misalignment of an adjacent indel

HDR High Discrepancy Region, Region contains many reads with multiple mismatches
MM Multiple Mismatches, Read contains multiple mismatches from reference
MV Multiple Variants, More than 1 non-reference variant at the same base location
MN MonoNucleotide run, Region contains pattern of repeat ex. AAAAAA
DN DiNucleotide run, Region contains pattern of repeat ex. AGAGAG
TR

Tandem Repeat, Region contains pattern of repeat ex. ACGACGACG

LCT Low Coverage in Tumor, Region contains low coverage in tumor
LCN Low Coverage in Normal, Region contains low coverage in normal
NCN No Coverage in Normal, Region contains no coverage in normal
TN

Tumor in Normal, Variant support in normal (common in blood cancers)

LVF Low Variant Allele Frequency, Variant has a low VAF
LM Low Mapping quality, Reads are poorly mapped
SI

Short Insert, Reads supporting variant result from short inserts

SIO Short Insert Only, Reads supporting variant contain only short inserts
SSE Same Start/END, Reads supporting variant have same start or end points
D

Directional reads, Majority of reads are in the same direction

E

End of reads, Variant only supported by the end of reads

AO Ambiguous Other, Provide an explanation not otherwise specified here

Glossary:
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Short Insert - Fragment sequenced twice because the paired end reads overlap (i.e. the insert
size is negative)

3.3.4 Validation sequencing
We designed a custom capture reagent for a data freeze of 488 loci of DoCM, comprised mainly
from the first four batches (“My Cancer Genome”, “Drug Gene Knowledge Database”,
“Literature”, “WashU hematologic malignancy mutation list”), using probes from Integrated
DNA Technologies (IDT, Coralville, IA). Probes that spanned these loci that were already
available in house were used and additional probes were designed around the remaining sites.
We attempted to validate 48 AML and 48 BRCA samples that had the most putative somatic
variants for which tumor and matched normal tissues were available. We created dual-indexed
libraries that were sequenced on HiSeq2500 (AML) and HiSeq2000 (BRCA) platforms with
paired 2x100 bp reads as previously described61,110.

3.3.5 Analysis of validation data
Custom capture reads were aligned to build 37 of the NCBI human reference genome (GRCh37)
using BWA (version 0.5.9) and duplicates were removed using picard (version 1.46). DoCM
sites were counted using bam-readcount (version 0.7.4) to assess coverage and perform
downstream analysis. Putative variants with at least 70x coverage and 5 or more reads of support
were classified as validated in the knowledge-driven approach. ClinSek version 0.1 was run on
the matched tumor and normal bam files for each validation sample using the spileup option with
default parameters and the DoCM data freeze as the site list104. The Bayesian classifier was run
using the Genome Modeling System (GMS)110 infrastructure at the McDonnell Genome Institute
using the ‘gmt validation identify-outliers command’ with a tumor purity value of 66% and a
normal contamination rate of 3%. Tumor purity and normal contamination values were estimated
71

using the mean rate observed in samples identified via manual review from the TCGA exome
data.

3.3.6 Bayesian Classifier Methodology
The following is an explanation of the methodology of the bayesian classifier used in the
manuscript. The program is integrated into the Genome Modeling System110 and can be ran
using the ‘gmt validation identify-outliers’ command as described below.
gmt validation identify-outliers
SNV/Indel calls were filtered through a Bayesian classifier to select only those sites that
were classified as somatic. Briefly, this classifier works by considering the likelihood of the data
being generated by 7 different binomial models. Each model’s log-likelihood function takes the
form:
logℒ(𝑁 , 𝑁 , 𝑇 , 𝑇 ) = 𝑁 log(1 − 𝜃 ) + 𝑁 log𝜃 + 𝑇 log(1 − 𝜃 ) + 𝑇 log𝜃

where 𝑁 is the number of reads supporting the reference allele in the normal sample, 𝑁 is the
number of reads supporting the variant allele in the normal sample, 𝑇 is the number of reads
supporting the reference allele in the tumor sample, 𝑇 is the number of reads supporting the
variant allele in the tumor sample.

Each of the different models defines 𝜃 and 𝜃 as below:
𝜖, 𝜖
⎧ 0.5,0.5
⎪
⎪1 − 𝜖, 1 − 𝜖
⎪
𝑓𝑐
(𝜃 , 𝜃 ) = 𝜖 +
,𝑓
𝑝
⎨
⎪ 0.5,1 − 𝜖
⎪
⎪ 0.5, 𝜖
⎩ 𝑓 ,𝑓

for the Reference model
for the Germline heterozygote model
for the Germline homozygote model
for the Somatic model

for the LOH variant model
for the LOH reference model
for the Noise model
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where 𝜖 is a constant error rate of 1%, 𝑓 is the observed variant allele frequency in the tumor, 𝑓

is the observed variant allele frequency at the site (across both samples), 𝑐 is the contamination
rate of the normal sample in the tumor, and 𝑝 is the purity of the tumor sample.

Sites pass the filter if the Somatic model has the maximum likelihood amongst all models and
the log-likelihood ratio of the Somatic model to the next most likely model is greater than 3.

Code available at:
https://github.com/genome/genome/blob/master/lib/perl/Genome/Model/Tools/Validation/Identif
yOutliers.pm

3.3.7 Code availability
Code for the DoCM web application are available at https://github.com/genome/docm.
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Chapter 4: Somatic Variant Refinement:
Recovering Cancer Variants Lost to Manual
Review
Ainscough, B. J. et al. in preparation (2017)
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4.1 Abstract
Cancer genomic analysis requires accurate identification of somatic variants in sequencing data.
While most steps in identifying somatic variants have been automated, manual review, or
‘somatic variant refinement’, is still required to remove false positives. However, this process of
manual variant refinement is time-consuming, costly, poorly standardized, and non-reproducible.
It remains, nonetheless, indispensable for accurate analysis of cancer data, especially as cancer
genomics is brought into the clinic, where it is increasingly used to guide therapy. Here, we
systematized and standardized somatic variant refinement using machine learning models, and
training data from 41,000 manually reviewed variant calls from 21 different studies representing
9 cancer types and 440 cases. The final model accurately reproduced the manual variant
refinement process, and accurately predicted which variants would be confirmed by orthogonal
validation sequencing data. Highlighting its significance, this approach identified several
clinically actionable variants missed by manual variant refinement, increasing the number of
actionable variants identified by 6.1%. These results indicate that systematization of the variant
refinement process can substantially increase the efficiency, accuracy, and reproducibility of
cancer genomic analysis.
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4.2 Introduction
Somatic variant callers are commonly used to identify somatic variants from aligned sequence
reads in cancer genomics studies and in clinical cancer assays 61. These callers attempt to
statistically model sample purity, sequencing errors, zygosity, ploidy, and other factors. Postprocessing (variant filtering and manual review) of somatic single nucleotide variants (SNVs) is
a process we term ‘somatic variant refinement’ and is an important next step and is distinct from
variant calling because it eliminates false positives from a candidate somatic variant list by
setting thresholds for a variety of metrics including read coverage depth, variant allele fraction
detected, base quality metrics, and others. The manual review of somatic variants is a process
that requires an individual to directly examine aligned reads using a read alignment viewer such
as IGV26 to identify common error patterns that are consistently missed by state-of-the-art
somatic variant callers75,115.
Somatic variant refinement often improves calls by taking into account information
neglected or unavailable to standard variant callers. Reviewers look for several patterns that can
increase or reduce confidence in a variant call, for example, (1) all supporting reads are oriented
in the same read direction; (2) independent fragment support is lower due to overlapping reads
from short DNA fragments; (3) alignment errors related to homopolymer stretches, short repeats,
or other low-complexity sequences; (4) supporting reads include multiple errors, indicating
possible misalignment; (5) variants consistent with tumor contamination of normal; (6) all
support occurs at the end of the sequencing reads, where overall error rates are higher; and
others(Figure 4.1).
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Figure 4.1 IGV Snapshots of common false positives that allow manual reviewers to filter out
artefactual somatic calls. (A) Example of Tandem Repeat (B) Example of a High Discrepancy Region (C)
Example of Same Start/End (D) Example of Multiple Variants at the same loci

If the number of problematic variant reads at a locus is high, a reviewer may eliminate the
variant identified by a somatic variant caller. Manual reviewers often balance several
observations to disqualify reads and make their final variant call.
Somatic variant refinement has a large impact on the final variant calls. A
previous study showed that up to 44% of calls made by variant callers are failed during the
variant refinement process116. Although post-processing of somatic SNVs can dramatically
improve the accuracy of somatic variant calling, filtering and manual variant refinement
strategies are often unstated or only briefly mentioned. Typically, methods for sequencing
studies will state, “Translocation calls were manually inspected in IGV“117, or “All indels were
manually reviewed in Integrative Genomics Viewer”118. Some methods do not even use manual
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somatic refinement and merely require, “coverage of at least 50 reads in both tumor and normal
samples, >20% of reads supporting the variant in tumor samples and <5% of reads supporting
the variant in normal samples”119. These are just a small sampling of a very prevalent history of
under-reporting the details of variant refinement processes from our institute and others

120.

As a

result, standardization of somatic variant calling or comparison between studies becomes nearly
impossible. Discrepancies in manual review operating procedures could result in major inter- and
intra-lab variability and error. To address the issue of reproducibility, our standard operating
procedure for somatic variant refinement can be found in Appendix 1. Additionally, while postprocessing variant calling is extremely important, it is very time-consuming and therefore,
expensive. Experienced reviewers can evaluate approximately 70-100 variants per hour and these
numbers are likely lower in clinical cancer NGS assays where consequence of mislabels are
greater. In one study completed by our lab, 10,112 variants were called by somatic variant
callers, 1,066 were filtered out using sequencing metrics, and 9,046 variants required direct
manual review. This manual review would have taken approximately 90-130 hours to complete
by highly trained staff116.
Previous studies have used machine learning algorithms to call somatic variants 121,122,
however these studies have had small training data sizes (fewer than 3,000 variants) or were
conducted with data from a limited number of cancer types. These studies have attempted to
automate somatic variant calling. However, the high quality, multi-factor filtering currently
provided by the manual refinement of putative somatic variant calls has not yet been
automated123. In this study, we demonstrate that machine learning can be used to systematize and
standardize somatic variant refinement, alleviating the manual review bottleneck.
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In this study, we present a model that automates refinement of variants called from sequencing
data. We show that the use of a model, as presented here, could substantially reduce a major
bottleneck in cancer genomic analysis while improving reproducibility and transparency in
genomic studies and in the clinical setting. This model is built on a training dataset of 41,000
variants from 21 studies with 440 cases, including 9 cancer types. All cases included paired
tumor and normal samples that had been evaluated by manual variant refinement, and required
an estimated 585 hours of effort. For each variant, we assembled 71 features to train the model
including cancer type, tumor and normal read depth, tumor and normal variant allele fraction,
base quality, mapping quality, etc. (Appendix 2). This dataset is an order of magnitude larger
than previous studies that utilized machine learning to detect somatic variants and has
representation across both solid and hematological malignancies, which have distinct genomic
signatures that often complicate somatic variant calling (Table 4.1). Additionally, this dataset
includes cancer types covering a broad range of average mutation burden, from leukemia on the
low end to lung cancer and melanoma on the high end. This broad representation should allow
the machine learning algorithms to generalize well across different cancer subtypes.
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Training Set

Testing Set

Total

(n=27,470)

(n=13,530)

(n=41,000)

Malignancy (410 cases)
Leukemia (243 cases)
Lymphoma (23 cases)
Breast (135 cases)
Small Cell Lung (18 cases)
Glioblastoma (17 cases)
Melanoma (1 cases)
Colorectal (1 case)
Gastrointestinal Stromal (1 case)
Malignant Peripheral Nerve Sheath (1 case)

5,815
1,263
8,986
9,177
844
185
842
70
288

2,877
628
4,320
4,601
412
100
419
31
142

8,692
1,891
13,306
13,778
1,256
285
1,261
101
430

Sequencing Methods
Capture Sequencing
Exome Sequencing
Whole Genome Sequencing

9,479
9,367
8,624

4,755
4,677
4,098

14,234
14,044
12,722

Variant Calls
Somatic
Ambiguous
Fail
Germline

12,266
7,189
5,909
2,106

6,115
3,454
2,945
1,016

18,381
10,643
8,854
3,122

Table 4.1 Overview of the cancer sequence data included in the training and testing set with regard to
malignancy, sequencing approach, and manual review variant calls.

Here, we present a deep learning classifier that automates manual review of aligned and
variant called sequencing data. We show that the use of a classifier as presented here could
substantially reduce a major bottleneck in cancer genomic analysis while improving
reproducibility and transparency in genomic studies and in the clinical setting.

4.3 Methods
4.3.1 Data assembly and standardization
We assembled manual review data from 21 different recent cancer genomic studies at the
McDonnell Genome Institute, including 11 genomic discovery cohorts, 1 clinical trial, and 9 case
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studies (Table 4.2)61,124-130. In total, 440 samples were evaluated, with 266 samples derived from
hematologic malignancies and 174 samples derived from solid tumors. Samples were only
included in the training dataset if paired tumor-normal sequencing data and manual review calls
were available. Since some samples were used in multiple studies, we eliminated sample
duplicates by removing all sample pairs with more than 70% co-occurrence of genomic
mutations. Sequencing data was produced from whole genome, exome, or custom capture
sequencing and all data were aligned to reference genome hg19/GRCh37 using bwa or bwamem17,131(Table 4.1).
Manual review for all projects was performed as outlined in Appendix 1. Reviewers
manually refine variants using 4 distinct classes: “somatic” (S) - a variant that has sufficient
support in the tumor in the absence of obvious sequencing artifacts; “ambiguous” (A) - a variant
with insufficient sequencing support to definitively classify the variant; “germline” (G) - a
variant that has substantial support in the normal sample beyond what might be considered
attributable to tumor contamination of the normal; and “fail” (F) - a variant with low variant read
support and/or reads that indicate sequencing artifacts, yet has acceptable variant coverage. As
reviewers call variants “ambiguous”, “germline”, or “fail”, they often provide additional notes
or tags describing the reason for each call; these tags classify common reasons for rejection. For
example, apparent deletions can be caused by misalignment of reads to tandem repeat regions in
the reference sequence (Figure 4.1A), high discrepancy regions can be caused by failure to
properly align to the correct homolog (Figure 4.1B), reads with the same start and end can be
caused by PCR amplification artifacts that were not removed by de-duplication software (Figure
4.1C), or multiple variants can be supported at the same loci (e.g. at a site with a reference allele
of A reads supporting a G and a T allele are present)(Figure 4.1D). “Germline” and “failed”
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calls enumerate two distinct types of failure, however, since germline and failed calls do not
invoke any downstream analysis procedures, they were merged into one class called “failed”.
Therefore, the machine learning classifier will make calls for “somatic” (true positive),
“ambiguous” (uncertain if somatic or failed) and “fail” classes. All manual review results were
standardized to a one based coordinate system using a Python tool developed for this purpose
(https://github.com/griffithlab/convert_zero_one_based). Relevant metrics were extracted from
the bam files using bam-readcount (https://github.com/genome/bam-readcount). Bam file metrics
were merged with cancer type and reviewer information. All continuous features were
normalized to fall between 0 and 1 using Scikit-learn’s MinMaxScaler132. All categorical
variables were one-hot boolean indexed to split any feature with n categories into a n column
boolean array. Following processing, the training dataset totaled 71 features (Appendix 2).
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Project Name

Cases (n=441)

Malignancy

Pubmed link

DBGAP
Accession #

MDS
Breast

Publication
status
In preparation
Submitted

GTB11
Benign Breast
Cancer
Traztuzamab

98
70
48

Breast

Published

phs001291.v1.p1

Relapse AML

47

AML

Published

AML
Decitabine
Folicular
Lymphoma
AML Quads

39

AML

Published

22

Lymphoma

Published

21

AML

Published

MDS
DECITABINE
SCLC
BKM120

20

MDS

Published

https://www.ncbi.nlm.nih.gov
/pubmed/28453704
https://www.ncbi.nlm.nih.gov
/pubmed/26305651
https://www.ncbi.nlm.nih.gov
/pubmed/27959731
https://www.ncbi.nlm.nih.gov
/pubmed/28064239
https://www.ncbi.nlm.nih.gov
/pubmed/26305651
https://www.ncbi.nlm.nih.gov
/pubmed/27740633

18
17

SCLC
Breast

In preparation
Published

AML Post
Transplant
Relapse
GBM
GST1

16

AML

Submitted

16
1

In preparation
Case study (no
publication)

GTB19

1

GTB2

1

Glioblastoma
Gastrointesti
nal Stromal
Tumor
Large
Granular
Lymphocytic
Leukemia
Melanoma

ALL1

1

ALL

Case study (no
publication)
Published

AML31

1

AML

Published

CRC1

1

Colorectal

DLBCL

1

Lymphoma

LGG1

1

Glioblastoma

MPNST

1

Malignant
peripheral
nerve sheath
tumor

Case study (no
publication)
Case study (no
publication)
Case study (no
publication)
Case study (no
publication)

https://www.ncbi.nlm.nih.gov
/pubmed/26563128

phs000159.v6.p4.
phs000159
phs001229.v1
phs000159.v6.p4.
phs000159
phs0001049
none in
publication

Case study (no
publication)

https://www.ncbi.nlm.nih.gov
/pubmed/27181063
https://www.ncbi.nlm.nih.gov
/pubmed/26645048

phs001066.v1.p1
phs000159

Table 4.2 Data Availability of Sequencing Results for all Cases Used in the Machine Learning
Classifier Development.

4.3.2 Model Development and Analysis
Logistic regression, random forest, and deep learning were tested as alternate models of somatic
variant refinement. A logistic regression classifier was implemented using the keras library
(https://github.com/fchollet/keras). Scikit-learn was used to implement the random forest
classifier132. The random forest was trained using the parameters n_estimators=1000 and trees
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max_features=8. The deep learning model was implemented using the keras library as a feedforward network with the input layer equaling the number of features, four hidden layers with
20-node hidden layers, and an output layer equaling the three outputs (‘somatic’, ‘ambiguous’,
‘fail’). The input and hidden layers used a hyperbolic tangent (tanh) activation function, the
output layer used a softmax activation function. Categorical cross-entropy was used as a loss
function and the Adam optimizer was used over 700 epochs with a batch size of 2,000. L2
regularization was used with a weight of 0.001.
To compare model performance, one-versus-all receiver operator characteristic (ROC)
curves were generated and area under the curve metrics (AUC) quantified using scikit-learn132. A
random subset of two thirds of the 41,000 variant dataset was used as a training set, and the
remaining third was withheld as a validation set. Scores for examples in the training set were
computed using ten fold cross-validation, so performance on the training set could be used to
estimate generalization accuracy132.
Feature importance for the deep learning model was calculated by training a model on the
cross-validation dataset, independently shuffling each of the 71 features, and determining the
change in average AUC, by comparing baseline and shuffled performance. The random forest
feature importance metric was obtained from scikit-learn’s built in feature_importances_
parameter on a trained random forest model.

4.3.3 Validation of model performance by independent sequencing data.
Orthogonal validation of variant calls can be obtained from a technical replicate of
sequencing data obtained independently of the data used by the manual reviewers. To assess the
machine learning model’s performance, we evaluated variant calls for a single acute myeloid
leukemia case (AML31) that had orthogonal validation sequencing. Ultra-deep whole genome
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sequencing data (average coverage = 312x) was previously produced for AML31 to evaluate
seven different variant callers. Orthogonal custom capture validation sequencing (average
coverage = 1000X) was used to validate mutations (n=192,241) identified by any of the seven
variant callers61. Variants identified as somatic by orthogonal sequencing (the “Platinum SNV
List”) were considered true positives (n = 1,343). Variants that were identified by only one of the
seven callers but not validated by ultra deep-sequencing were considered true negatives (n =
190,898). Features were obtained from whole genome bam files for every site that was called by
at least one of seven variant callers in the original study and had been selected for targeted resequencing (n = 192,241). The random forest and deep learning models (trained using the 41,000
call training dataset) were used to predict calls for each of the sites in the AML31 dataset and
receiver operator curve (ROC) figures were used to illustrate model performance.

4.3.4 Independent Test Set
To assess model robustness against batch effects, an independent test dataset was
assembled from 4 additional small cell lung cancer (SCLC) paired tumor-normal cases (2,686
variants). This independent test dataset had been sequenced on different instruments (HiSeq
2500 vs HiSeq 4000), utilized different false positive filtering thresholds, and was manually
reviewed by different individuals. To test model performance on these data, we trained a deep
learning and random forest model on the entire training dataset of 41,000 calls and made
predictions for the 2,686 calls of the independent test samples. We assessed the model
performance by creating ROC curves and reliability diagrams as outlined above.

4.3.5 Annotations of Clinical Relevance
All variants identified as somatic by either manual somatic refinement or by the classifier
(n=21,100) were evaluated for clinical significance. False positives were defined as variants
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identified as somatic by the manual review pipeline but labeled as ambiguous or fail by the
classifier. False negatives were defined as variants identified as ambiguous or fail during manual
review but identified as somatic by the classifier. Variants were annotated using two clinical
annotation databases (The Database of Curated Mutations (DoCM)115 and the Clinical
Interpretations of Variants in Cancer (CIViC) database99). Using the DoCM database, we
evaluated exact overlap (chromosome, start, stop, reference base, variant base) between DoCM
entries and misclassifications (i.e. false positives and false negatives). To evaluate overlap with
the CIViC database, coordinates were queried from the CIViC interface using the public API
(http://griffithlab.org/civic-api-docs/). Given that not not all variants within CIViC can be
analyzed using whole genome or whole exome sequencing, we used the Sequence Ontology IDs
to filter out variants that cannot be analyzed using DNA-sequencing, such as ‘increased
expression’ or ‘methylation’, etc. (Table 4.3). We queried coordinates from the CIViC interface
to determine overlap between CIViC annotations and misclassifications, such as therapeutic
sensitivity, therapeutic resistance, prognosis, diagnosis, or predisposing, were determined using
CIViC evidence statements.
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Table 4.3 Sequence Ontology IDs used to filter variants within the CIViC database that can be
analyzed on DNA-sequencing platforms.

4.3.6 Code and data availability
All analysis, preprocessing code, readcount training data, manual review calls and trained deep
learning and random forest models are available on github at
https://github.com/griffithlab/manual_review_classifier. Breast cancer cell line (HCC1395)
variants and manual review calls are included in the github repo to serve as test data110. All plots
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were produced using the MatPlotlib library133. Data availability for all the projects included in
this study are outlined in Table 4.2.

4.4 Results
4.4.1 Data assembly and standardization
The 41,000 variants used to train the model were derived from 440 individual tumors spread
across 9 cancer types. The sequencing approach used to assess tumor genetics was evenly split
between capture sequencing (14,234 variants), exome sequencing (14,004 variants), and whole
genome sequencing (12,722 variants). Among all manually reviewed variant calls, 18,381 were
confirmed as somatic, 10,643 were assessed as ambiguous, 8,854 as failed, and 3,122 as
germline. The training data has representation of both hematopoietic (10,583 variants) and solid
tumors (30,417 variants), which often have distinct characteristics during manual variant
refinement (Table 4.1).

4.4.2 Machine Learning Model Development and Analysis
We developed three models (logistic regression, random forest, and deep learning) using the
41,000 call data set. To test against overfitting, we randomly selected one third of the dataset as a
holdout test set and used the remaining two thirds as a training set in a 10-fold cross-validation
strategy for model development. In the 10-fold cross-validation, all three models (logistic
regression, random forest, and deep learning) achieved better than random performance on the
classification of somatic variants. The logistic regression model demonstrated the worst
performance, indicating that a linear separator is insufficient for adequate classification (average
AUC=0.89). Specifically, it showed limited ability to classify ambiguous calls (AUC=0.79),
which is the most poorly defined of all the variant classes. However, both random forest and
deep learning models performed very well across all classes attaining an average AUC of 0.98
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and 0.96 respectively (Figure 4.2A). The random forest and deep learning models perform
similarly across all three classes. The holdout test set also performed similarly (average AUC =
0.97) to the prior 10-fold cross validation (Figure 4.3A).

Figure 4.2 Deep learning and random forest method achieve excellent classification performance on
manual review calls. (A) Comparison of performance of various machine learning models via receiver
operating characteristic (ROC) curve for the three classification classes in the cross-validation data. The
diagonal line indicates baseline performance. The deep learning and random forest classifiers perform
approximately identically. (B) The deep learning and random forest classifier outputs are well scaled to a
probability (between 0 and 1). The bar graphs plot the distribution of model output that agrees with the
manual review call versus output that disagrees with the call in 10 equally distributed bins of model
output. The diagonal line indicates a perfectly scaled probabilistic prediction. The colored points display
the ratio of predictions that agree with the call to the total number of predictions for a given bin.
Binomial proportion confidence intervals were calculated for each bin. Pearson’s correlation coefficient
comparing colored points to the diagonal line was calculated to assess the output of the respective model.

Reliability diagrams were used to determine if model outputs could be interpreted as a
probability of a variant call. Model output, which was a continuous value, was plotted for 10
equally distributed bins that were separated by whether the model’s output matched or did not
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match the manual variant refinement call. For each bin, we calculated the ratio between the
number of sites where the model agrees with the call and the total number of sites in the bin. It is
expected that if the model output estimates a well-scaled probability, then the calculated ratio
will be correlated to an identity line (x=y). Pearson’s correlation coefficient was used to test for a
well-scaled probability using the scipy.stats.pearsonr function134. Comparing the reliability
diagrams for each model indicated that the random forest model and the deep learning model
produced outputs that are most closely scaled to a probability. The random forest model and the
deep learning model obtained a pearson’s correlation coefficient (r) of 0.99 and 1.00,
respectively (Figure 4.2B). The logistic regression model output was most divergent from a
well-scaled probability with r=0.29. When reliability diagrams are plotted independently for each
class (somatic, ambiguous, and fail), all classes produce well-scaled output (Figure 4.4).
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Figure 4.3 Deep learning manual review classifier performs well on hold out test data, and on cross
validation results with a simplified disease feature and the reviewer removed. ROC curve and reliability
diagram performance of the deep learning classifier with the cancer type feature distilled down to solid
tumor status. Performance of deep learning model on a ⅓ holdout test set of the original training dataset.
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Figure 4.4 Deep learning model outputs are well scaled across all predicted classes. The correlation
between the model output and the manual review call to a well scaled probability was assessed for all
three different classes of calls: ambiguous, fail, and somatic. The probabilities for each class were binned
into 10 classes ranging from 0.00-1.00. For each bin, the total number of manual review calls that agree
and disagree with the individual class were plotted. The ratio of agreement to disagreement was plotted
for each bin and compared to the identity line (x=y) using the Pearson's correlation coefficient (r).

4.4.3 Feature Importance
Feature importance analysis was used to determine which features each model was relying upon
to make predictions. The deep learning model ranked feature importance using the average
change in the AUC after randomly shuffling individual features, and the random forest model
using the built-in feature importance metric. To assess how manual reviewers rank the
importance of different features, seven manual reviewers at our institute were asked to rank their
top 15 (of 71) features, that were most important in their manual review decision-making
process. The average importance of features to the reviewers was used as a comparison to the
model feature rankings. All three importances were rank normalized for comparison.
Comparison shows that the models rely on many features that expert manual reviewers also use
to make classification decisions (Figure 4.5). The random forest feature importance was
moderately correlated to the deep learning and manual reviewer feature importance (Pearson’s r
= 0.47 and 0.48 respectively). The deep learning importance was only weakly correlated with
manual reviewer survey results (pearson’s r=0.11). Of note, both the random forest model and
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the deep learning model ranked reviewer higher than reviewers themselves ranked this feature.
Similarly, cancer type was ranked in their top 5 most important features of each model, however,
this was not ranked heavily by manual reviewers.
We hypothesized that most of the value of the cancer type feature is mediated by
differences between liquid and solid tumors. This is because, the normal sample of
hematological cancers is more likely to be contaminated by cancer cells than in solid tumors and
requires special consideration. This contamination ultimately increases the risk that a somatic
variant will be mis-called. To test this hypothesis, we collapsed the cancer type features to a
single solid/liquid boolean. Comparison of model performance with parsed tumor types to model
performance with simplified tumor type (solid/liquid) showed similar performance (Figure
4.3B). This supports our hypothesis that the distinction between liquid and solid tumors is
important for calling variants accurately and individual disease type is not as important beyond
this key difference.
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Figure 4.5 Deep learning and random forest models use similar features to manual reviewers in
making manual review classification decisions. Most features ranked as important by RF and deep
learning models agree well with features that human manual reviewers rank highly for classification
decisions. Human manual reviewer feature importance was determined by asking 7 individuals who have
contributed to manual review data to rank feature importance. Single feature impact for the deep
learning model was obtained by training a model on the entire training dataset then shuffling each
feature individually and calculating the mean ROC AUC for all three classes. The change in mean ROC
AUC for all classes was sorted and plotted. Random forest feature importance was obtained via scikitlearn’s feature importance parameter. The random forest feature importance is moderately correlated to
the deep learning and manual reviewer feature importance (pearson’s r= 0.47 and 0.48 respectively).
The deep learning importance was weakly correlated with manual reviewer survey results (pearson’s
r=0.11). All feature importance metrics were ranked normalized. The top 30 most important features
(average rank), of the three metrics, are shown.

4.4.4 Inter-reviewer Variability
Reviewer identity was also an important feature, among the top 30 features, which indicates
reviewer-specific patterns in manual review. Consequently, we studied the inter-reviewer
variability. To quantify the variability between manual reviewers we had three independent
reviewers call a random subset of 176 sites from the training dataset. This resulted in 3
independent review calls for each of the 176 variants. The calls were randomly chosen from the
training cohort and represent various malignancies. Reviewers achieved fair agreement with a
Fleiss’ Kappa statistic of 0.37, which is a statistic that lies between -1 and 1 where a Kappa
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statistic below 0 indicates poor agreement and above 0 indicates good agreement. When
evaluating all calls in the inter-reviewer variability analysis, 77.3% of all calls showed
reasonable agreement (i.e. all three reviewers agree on the call or two reviewers agree on the call
and the third reviewer labels the call as ‘ambiguous’) (Figure 4.6A). Model performance was
correlated with reviewer agreement such that when all three reviewers call a variant as ‘somatic’,
the model produces a high ‘somatic’ probability (output above 0.8). Conversely, when all
reviewers agree that a call is ‘fail’ the model produces a low somatic probability (below 0.2). As
expected, in times of inter-reviewer disagreement, the model produces a wider distribution of
‘somatic’ probabilities (Figure 4.6B-C). Together, these results indicate that there is as much as
22.7% disagreement among reviewers, especially on ambiguous calls.
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Figure 4.6 Manual reviewers exhibit varied inter-reviewer agreement; however, model confidence
closely parallels reviewer confidence (i.e. when all reviewers agree the model give high probabilities,
when reviewers disagree the model assigns lower probabilities). (A) The binned agreement of 3
reviewers on 176 variants. The x-axis outlines all possible permutations of agreement among three
reviewers. The y-axis outlines the frequency of each group of agreement. ‘S’ denotes a somatic call, ‘A’
denotes ambiguous, and ‘F’ denotes a fail call. ‘SSS’ is the case where all three reviewers call the same
variant somatic and the other permutations follow a similar pattern (e.g. ‘SAF’= somatic, ambiguous,
fail). It is considered 1) good agreement when all three reviewers agree, 2) acceptable agreement when
reviewers only disagree between ambiguous and somatic or ambiguous and germline calls, 3) and poor
agreement when one reviewer gives a somatic call another fail on the same variant. Problematic sites are
where one reviewer calls a variant somatic while another calls a variant fail. (B) Violin plots of deep
learning somatic probability, the horizontal lines indicate the occurrence of a probability and the width
indicates the distribution of probabilities. (C) Violin plots of random forest somatic probability.

Variant calls that do not depend on reviewer identity are most desirable for
reproducibility, and to reduce the impact of idiosyncratic criteria. Previous analysis used 71
features, whereby one feature was the individual who performed manual review. New models
were developed after removing the reviewer feature from the training data to assess performance
in situations when the reviewer is unknown. The deep learning model with all 71 features
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resulted in an average AUC of 0.960 compared to an average AUC of 0.956 with the reviewer
feature removed. This experiment illustrates expected performance on de novo data that does
not include a reviewer feature (Figure 4.4C).

4.4.5 Validation of model performance by independent sequencing data.
All the variant sites in our training and independent test datasets were obtained through matched
tumor-normal genomic sequencing, variant calling via statistical somatic callers, various filtering
strategies, and finally manual variant refinement. To understand how our model performs on
unfiltered “raw” variant calls, we ran our model on 192,241 putative somatic variants called by
one of seven variant callers in a rich sequencing dataset described by Griffith et al.61. In addition
to the ultra-deep whole genome sequencing available in this study for discovery, orthogonal
custom capture validation sequencing was performed on all 192,241 sites. Sites validated by the
custom capture data were considered positives and those that failed considered negatives.
Comparing somatic model predictions from the random forest model and the deep learning
model to validation sequencing results achieved a ROC AUC of 0.96 and 0.95, respectively
(Figure 4.7).
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Figure 4.7 Deep learning and random forest classifiers accurately predict orthogonal validation
sequencing results. Across 192,241 putative somatic variants identified by one of 7 variant callers in a
single AML case with 300x whole genome sequencing data the random forest classifier accurately
validation obtained from 1000x orthogonal validation sequencing data.

4.4.6 Independent Manual Review Data
To test model performance on independent data, we obtained a sample set that was sequenced
independently, underwent a different filtering strategy, and was reviewed by new manual
reviewers. This dataset had 2,686 manual review calls and genomic data from 4 paired tumornormal small cell lung cancer (SCLC) cases. This dataset had a different distribution of call
classes (94.1% somatic, 5.4% fail, and 0.5% ambiguous) when compared to the training cohort
(44.8% somatic, 29.2% fail, and 26% ambiguous). The independent test dataset had an average
AUC of 0.70 for random forest and 0.81 for deep learning (Figure 4.8A). We tested ways to
overcome batch effects between SCLC tumors in the training set and SCLC tumors in the
independent test set. To overcome the apparent batch effect, we randomly selected manual
review calls from the independent test set in 5% increments from 0% to 75% to include in
training the model. We then tested the performance of the newly trained model on the remaining
manual review calls from the independent test set. For the deep learning model and the random
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forest model, model performance was restored to levels observed in cross-validation after
inclusion of approximately 250 manual review calls (Figure 4.8B).

Figure 4.8 The deep learning classifier performs better than the random forest on validation
sequencing data. (A) ROC curves outlining deep learning and random forest model performance on the
independent test dataset consisting of 4 SCLC cases with 2,686 variants. (B) Independent test set batch
effect correction. Independent test set data was partitioned in random stratified increments of 5% from 075% of the total independent test dataset size and used to train a new model. The x-axis outlines the
number of test variants included in training. The y-axis plots the resulting model’s ROC AUC. The
ambiguous class shows significant stochasticity due to low representation in the test dataset (n=15).
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4.4.7 Recovery of Clinically Actionable Variants
The deep learning model was used to assess if machine learning algorithms for variant analysis
could improve detection of true clinically actionable mutations mislabeled by traditional variant
post-processing strategies. Of the 21,100 variants identified as somatic by either the deep
learning model or by manual variant refinement, there were 16,722 variants that were called as
somatic by both methods, 1,659 variants called as somatic only by manual variant refinement
(i.e. false positives), and 2,719 variants that were called as somatic only by the deep learning
model (i.e. false negatives) (Figure 4.9).
Mislabeled variants were evaluated for biological importance using the Database of
Curated Mutations (DoCM). DoCM is a database that outlines literature supported biologically
important and clinically relevant variants. Of the 2,719 false negatives identified by the deep
learning model, 8 variants had an exact match with an annotation in DoCM. There were 110 total
publications associated with these variants with an average of 13-14 publications per variant. The
average model output for the somatic class of all 8 variants identified in DoCM was 0.877. Of
the 1,659 false positives identified by the deep learning model, 12 variants had an exact match
with an annotation in DoCM. There were 93 publications associated with the variants. The
average model output for the somatic class of all 12 false positives identified in DoCM was
0.256 (Figure 4.9 and Table 4.4). The classifier could properly call several clinically actionable
variants, as determined by DoCM, that had been improperly labeled by manual review.
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Figure 4.9 Manual review misclassification rectified by the deep learning model. The venn diagram
illustrates variants identified as somatic by only the manual review model (false positives), only the deep
learning model (false negatives), and by both pipelines (true positives). For these three groups, we
showed the number of variants that have direct overlap with both DoCM Annotations and CIViC
annotations. For DoCM annotations, we listed the total number of publications associated with with all
variants within each group. For CIViC annotations, we listed the total number of evidence items
associated with all variants within each group. These evidence items are parsed by those that convey
variant sensitivity to a drug, variant resistance to a drug, variant that confers better or worse prognosis,
variant that confers disease diagnosis, and variant shows predisposing evidence for disease. Re-review of
the 53 false positive somatic variants with CIViC annotations showed that 44 were erroneously called
somatic by original manual reviewers. Similarly, re-review of the 40 false negative somatic variants with
CIViC annotations showed that 39 variant were erroneously failed original manual review.
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A

B

Table 4.4 There was a high level of exact overlap between false negatives recovered by the machine
learning classifiers and DoCM annotations. For each table, the ‘Probability’ is the output of the
classifier, the ‘MR call’ is the call made by the human manual reviewer, the ‘Classifier’ is the call made
by the machine learning model, and the ‘Publications’ is the total number of publication hits within the
DoCM database. (A) This table shows false negative calls derived from the Deep Learning classifier that
had exact overlap (chr, start, stop, ref, var) with DoCM annotations. (B) This table shows false negative
calls derived from the Random Forest classifier that had exact overlap (chr, start, stop, ref, var) with
DoCM annotations.

Mislabeled variants were also evaluated for clinical relevance using the Clinical
Interpretations of Variants in Cancer database (CIViC)99. CIViC is a freely accessible database
that promotes community-driven expert curation of clinically relevant variants in cancer. Each
annotation within CIViC is based on evidence summaries that detail therapeutic, prognostic,
predisposing, or diagnostic implications in cancer. Based on filtering using the sequencing
ontology IDs (see section 4.3) to remove annotations that could not be analyzed using DNA
sequencing, there were 425 clinically relevant CIViC annotations. Of the false negatives
identified by the deep learning model, 40 variants were actionable with 100 evidence items
related to therapeutic sensitivity, 18 evidence items related to therapeutic resistance, 54 evidence
items detailing prognostic information, 17 indicating diagnostic information, and 1 evidence item
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that supported predisposition for cancer. Of the 1,659 false positives that were reclassified as
‘fail’ by the deep learning model, there were 53 clinically relevant variants that had overlap with
CIViC. Of these false positives identified by the deep learning model, there were 90 evidence
items related to therapeutic sensitivity, 25 evidence items related to therapeutic resistance, 87
evidence items detailing prognostic information, and 18 illustrating diagnostic information
(Appendix 3). There are, therefore, several clinically actionable variants from the CIViC
database that were mislabeled by manual review and rectified by the model.
Retrospective review of these mislabeled variants in Integrative Genomic Viewer (IGV) 26
confirmed confidence in model predictions. When re-reviewing the 53 false positives, 83%
(44/53) were determined to be miscalls by the original manual reviewer. Four examples of
manual review miscalls are shown in Figure 4.10. Of the 9 variants whereby the original manual
review was deemed correct and the model was incorrect, 6 were small insertions, indicating a
potential issue with the model’s ability to properly label small insertions as somatic. When rereviewing the 40 false negatives, (39/40) 97.5% appeared to be high quality somatic cells
erroneously called ambiguous or fail by the original reviewer. In one example, 2 clinically
relevant PIK3CA mutations were missed due to the manual reviewer assuming that two adjacent
variants on the same strand were considered multiple mismatches (Figure 4.11). In another
example a TP53 mutation was missed in an acute myeloid leukemia case due to the manual
reviewer’s lack of recognition that hematologic cancers typically have tumor contamination in
normal tissue (Figure 4.11). According to the re-review of false positive and false negative calls,
the model is more sensitive and specific than the data on which it was trained.
The manual variant refinement workflow identified 92.1% of all eligible clinically actionable
mutations. In contrast, the deep learning model identified 98.2% of all possible clinically
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relevant variants. Therefore, the model was able to recover 6.1% more variants than a traditional
manual approach. Similarly, 8.9% of variants (n=44) were false positives via manual variant
refinement whereas 0.2% (n=1) false positives were reported using the model. Therefore, we
predict that model use would reduce total number of misreported variants to physicians by as
much as 8.7%. This result suggests that automated models of variant refinement might ensure
more accurate and reproducible analysis of cancer genome data, alleviating a key bottleneck in
analysis.
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Figure 4.10 IGV snapshots of clinically relevant false positives that were mislabeled during manual
review as somatic but re-identified as failed using the Deep Learning classifier. A. Failure due to short
inserts and directional artifacts. B. Failure due to directional artifacts C. Failure due to adjacent
mismatches and directional artifacts. D. Failure due to ends artifact.
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Figure 4.11 Manual visualization for two clinically relevant variants recovered by classifiers using
IGV showed evidence of mislabeling by manual reviewer. Within IGV snapshots, the normal tracks and
the tumor tracks show aligned reads that were obtained from normal tissue and the tumor tissue,
respectively. Variant loci are bracketed by horizontal grey bars. Variant summaries obtained from CIViC
show gene name, variant type, variant coordinates, clinical summary, and relevant clinical action items.
(A) Reviewer conservatively labeled both PIK3CA variants as ambiguous due to multiple mismatches in
reads, however, both variants appear to be somatic. (B) Evidence of tumor variant reads in normal track
can be attributed to tumor derived from patient with AML.
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4.5 Discussion
The random forest and deep learning models achieved excellent classification performance with
comparable performance across all variant refinement classes (somatic, ambiguous, and fail),
whereas the logistic regression model achieved poorer performance, particularly with the
ambiguous class. High performance of model predictions on cross validation data and hold-out
test set confirms the ability of an automated strategy to dramatically reduce the need for manual
variant refinement. Our ability to virtually eliminate manual review was further demonstrated by
removal of the manual reviewer as a feature for training the model. Attaining high performance
with and without reviewer information provides the ability to extrapolate the trained model onto
new data with an unknown reviewer (Figure 4.3C). Through our inter-reviewer analysis, we
elucidated that inter-reviewer agreement can be as low as 50% (Figure 4.6A), therefore, the use
of a machine learning algorithm for automated somatic variant refinement should also produce a
more reproducible and consistent result.
Suggesting a path to further improvements in cancer genomics pipelines, high accuracy
on orthogonal validation data suggests that the machine learning models might even reduce the
need for validation sequencing. Both the deep learning and random forest models showed high
accuracy in an independent test sample for classifying the validated Platinum Level SNVs
outlined by Griffith et al.61. Given a high level of sequencing data (300X coverage), we are
confident that the machine learning model classifies variants with a high accuracy even without
performing any manual review to train the model. Future investigation could explore downsampling reads to show if decreased variant signal alters model performance. While the
performance of the deep learning model on the independent test data (SCLC samples) was less
than the internal cross validation, the random forest model performed noticeably poorer. This
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decrease in performance could be due to batch effects, reviewer differences, or model
overfitting. However, introduction of as few as 250 calls from the independent test set in
training is a viable option to recover high performance (Figure 4.8B). We recommend manually
reviewing a small subset of variants called via statistical variant callers (e.g. 200-1000) to
evaluate model performance on new datasets. This will elucidate if the existing model has
decreased performance due to potential batch effects. If necessary, model performance can be
restored by including a small subset of manually reviewed variants into the training data and
retraining the model.
These results together show that a machine learning model can be effectively used to
automate variant refinement. Automation of variant refinement allows for standardization and
systematization of identifying putative somatic variants. This decreases the human variability
associated with any manual process and increases the reproducibility of variant
calling. Additionally, automation of variant refinement eliminates a labor bottleneck, and its
associated costs, allowing any number of somatic variant calls to be evaluated in a negligible
amount of time. Finally, since the model offers probabilistic output, an economic framework can
be used to set thresholds for confirmatory follow up testing allowing investigators to optimize
experimental design to improve accuracy within budgetary constraints 135.
To illustrate the extent of this advance, compared to a standard cancer genomics analysis
workflow, for a hypothetical whole genome breast cancer study with 100 tumor/normal paired
cases, there would be approximately 2,300,000 variants identified via somatic mutation callers.
Following a similar filtering strategy to a recent study in our group, these variants could then be
filtered to a set of approximately 25,000 variants needing manual variant refinement after
applying standard false positive filters129. This equates to about 360 person hours of manual
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variant refinement, if a typical reviewer processes 70 variants per hour. A machine learning
based automated approach would essentially eliminate this manual labor burden. To ensure that
the model’s training data is optimized for the hypothetical breast cancer data and corrected for
any associated batch effects (Figure 4.8B), 1000 randomly selected variants could be manually
reviewed, resulting in ~14 person hours of manual review. In this hypothetical example the
manual review burden would be reduced from 360 hours to ~14, a major improvement 25 times
more efficient.
It is apparent that automated models perform as well or better than manual review for
somatic variant refinement. Employing the model, relative to manual review, allowed for a 5.0%
increase in variants reliably detected and 6.1% increase in identification of known clinically
relevant variants. Using the automated approach can thus recover therapeutic opportunities,
elucidate potentially resistant therapeutics, predict prognosis and stratify relapse risk. For
example, Figure 4.11 showed a missed TP53 mutation in a patient with acute myeloid leukemia.
Based on evidence outlined in CIViC, this TP53 mutation suggests poor prognosis, which could
be important information when making treatment decisions for patients with AML. Given that
variant interpretation is one of the main barriers preventing genomic analysis for clinical
workflows76, the ability to reduce manual effort while improving the accuracy in detecting
clinically relevant variant calls could facilitate integration of genomics data into clinics.
This model does have some limitations. Since manual variant refinement calls are far from the
gold standard of somatic variant identification, the training data likely contains a substantial
amount of noise due to inter-reviewer variation, as shown in our analysis. In an ideal scenario,
highly accurate and orthogonal validation sequencing would be performed to determine somatic
variant status. Unfortunately, validation sequencing has a large monetary and tissue material
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expense, limiting our ability to use this type of data in the training set. Lastly, while the training
data was produced using a varied array of capture strategies, libraries, and Illumina sequencing
instruments, the model will likely require evaluation and some amount of retraining for nonIllumina sequencing instruments and divergent somatic variant analysis pipelines. It is also
possible that the model has learned various other institutional batch-effects from our sequencing
and analysis workflows. However, our results suggest that retraining with a small amount of
supplemental calls from an independent dataset may be sufficient to overcome these effects.
Finally, while this study demonstrates impressive performance on somatic variant
classification there is room for improvement with the use of additional genomic and sequencing
features such as proximal sequence complexity (e.g., presence of repeat regions), functional
prediction (e.g., conservation based variant impact scores), and other indicators associated with
false positives. Additionally, this problem is an ideal candidate for implementing active
learning136, that could continuously update and improve the model on low performing cases. The
assembly of a large gold standard somatic variant dataset that has validation sequencing results
and pan cancer representation could yield a substantial improvement in somatic variant
refinement performance over state-of-the-art filtering and manual review approaches.

4.6 Authors and Contributions
Benjamin J. Ainscough1,2, Erica K. Barnell1, Malachi Griffith1,2,3,4, Thomas E. Rohan,
Ramaswamy Govindan2,3, Elaine R. Mardis5,6, S. Joshua Swamidass7*, Obi L. Griffith1,2,3,4*
1

McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO,
USA.
2 Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
3 Division of Oncology, Department of Medicine, Washington University School of Medicine,
St. Louis, MO, USA.
4 Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA.
5 Institute for Genomic Medicine, The Research Institute at Nationwide Children's Hospital,
Columbus, USA.
111

6

Department of Pediatrics, The Ohio State University College of Medicine, Columbus, USA.
Department of Pathology and Immunology, Washington University School of Medicine, St.
Louis, Missouri, USA.
*Corresponding author
7

BJA wrote the manuscript, assembled and cleaned training data, performed model
training and analysis, and wrote all code. EKB performed manual review, analysis, and wrote the
manuscript. RG and TER shared genomic data that was used in training the classifier. MG, SJS,
ERM, and OLG supervised the project and revised the paper.

4.7 Acknowledgements
We would like to thank Allegra Petti, Gue Su Chang, Tiandao Li, Chris Miller, Lee Trani,
Robert Lesurf, Zach Skidmore, Kilannin Krysiak, Avi Ramu, Felicia Gomez and Alex Wagner
for assisting in data assembly. We also acknowledge Lee Trani for performing manual review on
the HCC1395 cell line and Lee Trani and Alex Wagner for valuable discussion on the project.
We gratefully acknowledge Lukas Wartman, John DiPersio, and Tim Ley for sharing genomic
data that made this project possible. The data on benign breast disease were generated through
grants to TER from NIH/NCI (R01CA142942) and the Breast Cancer Research Foundation.
Select sample data was funded by the Genomics of AML PPG (T.Ley, PI, P01 CA101937). BJA
was supported by the Siteman Cancer Center. SJS is funded by the National Library of Medicine
(NIH NLM R01LM012222 and NIH NLM R01LM012482). MG is funded by the National
Human Genome Research Institute (NIH NHGRI R00HG007940). OLG is funded by the
National Cancer Institute (NIH NCI K22CA188163 and NIH NCI U01CA209936).

112

Chapter 5: Conclusions and Future
Directions
The research presented herein will result in a significant improvement in quality and
reproducibility to somatic variant identification. Openly licensed, open access curated somatic
variant knowledgebases, like DoCM described in Chapter 2, aim to enable automated utilization
of the cancer genomics literature in computational workflows. The knowledge-driven variant
discovery strategy, described in Chapter 3, permits sensitive detection of known, clinically
relevant and functionally important cancer variants, which has broad utility both in research and
clinical sequencing analyses. Finally, by automating the post-processing of somatic variant calls
through machine learning (Chapter 4), the analysis time needed in MPS-based cancer studies will
be reduced dramatically, while enabling more reproducible and data-driven variant identification.
These improvements also lift the technical limitation on the number of somatic calls that can be
evaluated, in contrast to the time constraints imposed by manual analysis.

5.1 DoCM: a Database of Curated Variants in Cancer
In Chapter 3, DoCM, a Database of Curated Mutations in Cancer (http://docm.info), is described.
DoCM is an open source, openly licensed resource that enables the cancer research community
to aggregate, store and track biologically important cancer variants. DoCM is currently
comprised of 1,364 variants in 132 genes across 122 cancer subtypes, based on the curation of
876 publications. Due to the massive growth in the cancer literature (see Figure 3.6) it is a
laborious task to accurately catalogue the mutations whose importance in cancer has been
defined. Crowdsourced, open resources can help address this enormous problem.
While DoCM is a substantial improvement on earlier resources in terms of its size and
utility in computational pipelines, it is far from a comprehensive listing of all the important
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mutations discovered in cancer. In fact, many similar cancer variant resources that have been
released following DoCM, like CIViC124, have minimal variant overlap, suggesting that there is a
need for many more individuals to focus on the curation problem and to develop resources that
aggregate curation results.

5.2 Knowledge Based Variant Discovery of Functional
Variants
The use of DoCM to focus knowledge-based discovery of biologically or functionally important
cancer mutations resulted in the recovery of at least one functionally important variant in 41% of
TCGA cases examined (Chapter 3). These results demonstrated that 1,228 variants from four
TCGA studies that were missed by the original sequencing analysis pipeline could be recovered
through DoCM-guided discovery. Approaches such as this can rescue true variants that may be
important to identify in clinical assays of cancer DNA that aim to identify pathogenic mutations
with corresponding targeted therapies.
The MSRV approach, outlined in Chapter 4, could reliably recover missed somatic
variants through validation sequencing-based confirmation. However, the process was limited by
a high manual review burden and validation sequencing cost. Additionally, the heuristics used to
identify putative variants and validate the findings leave room for skepticism regarding the
consistency and bias of the approach. This study motivated the development of the machine
learning classifier, described in Chapter 4, to address these limitations by substantially
decreasing the manual review burden, and providing a measure of statistical confidence to
inform subsequent decision-making.
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5.3 Automation of Manual Review through a Machine
Learning Classifier
The results in Chapter 4 illustrate that a machine learning-based classifier can automate manual
review with excellent performance. Specifically, the deep learning approach we developed
classifies somatic calls with a ROC AUC of 0.98 in cross-validation performance, 0.89 on an
independent sequencing dataset, and 0.95 on an independent dataset with orthogonal sequencing
validation data. It is particularly promising that this method can accurately predict orthogonal
validation sequencing results, since these often represent a necessary, time-consuming and
expensive step in cancer variant discovery studies. With further assessment, confidence in
somatic variant calls evaluated with this approach could obviate orthogonal validation. Even if
validation sequencing remains a necessity, an economic framework can be used in conjunction
with the probabilistic output of the classifier to help investigators to tune somatic variant
discovery to be most efficient for their budgets 135. Additionally, the machine learning classifier
provides a standardized, consistent, and reproducible analysis strategy that will facilitate
improved inter- and intra-pipeline comparison, facilitating quantifiable somatic variant
identification performance for the entire variant identification pipeline between runs in the same
lab and between individual labs. This could help reduce the inter-pipeline variability seen across
many genomic datasets62.
While the machine learning classifier is extremely promising, there are several caveats
and limitations that should be considered when using it. Since the classifier was trained on data
from 20 different projects at the same institute (sequenced with similar laboratory procedures,
sequencing instruments, and a standardized analytical pipeline) it remains to be demonstrated
that the classifier will deliver consistent results on data produced under different circumstances.
Additionally, while the training data set is large and represents various cancer types, it is far from
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a comprehensive representation of all cancer types. Lastly, while the classifier’s performance
compared to validation sequencing results was highly comparable, it should be noted that this
sample had substantially more coverage than is typical in most studies in the peer-reviewed
literature (300-fold WGS discovery sequencing and 1000-fold custom capture validation
sequencing compared to typical studies that achieve targets of 60-fold and 200-fold coverage in
WGS discover and custom capture validation sequencing, respectively).
There are several future analyses that can improve the classifier. Additional evaluation of
model performance on sequencing data produced at various sequencing centers, at various
coverage levels, and with a variety of cancer types and analysis pipelines should be performed to
test the model’s robustness to global differences from single-center data. In the short term, the
model could be improved by and would be well suited to an active learning implementation,
where the machine learning algorithm sends low confidence calls to a human reviewer, and then
is iteratively trained based on the results, to further improve model performance. Such a scheme
could train the classifier to actively adapt to changes in sequencing protocols and analysis.
In the longer term, the success of this approach on the automated post-processing of
somatic variant calls, coupled with the application of machine learning algorithms to call
germline variants, could yield a machine learning algorithm well suited to somatic variant calling
that might replace, rather than simply supplement, existing callers 137. This development would
require a large training dataset that has good representation from a variety of cancer types,
sequencing pipelines, and analysis workflows, and with high quality validation sequencing
results, to serve as training data. While collecting such a dataset would require investment of
time and resources, it is likely based on our results that it would outperform existing options.
Given the extensive number of cancer genomes already sequenced by TCGA and ICGC, the
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production of a such a training dataset could be accomplished by performing extensive validation
sequencing on previously identified somatic mutations if the initial sample DNAs were still
available.

5.4 Conclusion
The research presented in this dissertation describes methods that substantially reduce the time
and cost to identify, analyze, and prioritize somatic cancer mutations while simultaneously
increasing somatic variant calling accuracy and the number of clinically relevant mutations
identified. DoCM reduces interpretation time by providing an open resource to catalogue the
results from publications that describe the clinical or functional impact of known somatic
mutations in cancer. This reduces the literature review that is duplicated every time a somatic
variant is identified and evaluated by different studies. The machine learning-based classifier is
not limited by human time to review variants, as such orders of magnitude more somatic variant
calls can be classified, while simultaneously reducing required manual review by an order of
magnitude. This classifier also improves on prior methods by providing a concrete probability
that represents the confidence of a variant call. Additionally, the DoCM MSRV approach
recovers at least one clinically or biologically important somatic mutation in as many as 41% of
samples evaluated (see subsection 3.3.5), while the manual review classifier improves the
identification of clinically important variants because substantially more variants are classified.
The results of this dissertation suggest that there is substantial room for development to improve
detection of somatic cancer mutations as genomics is translated into clinical use. As shown in
Figure 4.7, it is possible for machine learning methods to accurately predict which somatic
variant calls will be validated by orthogonal validation sequencing. Given this result, it is
plausible that future model development and evaluation could lead to the elimination of
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confirmatory validation sequencing of somatic variants. The results of this dissertation increase
the potential to apply cancer genomic data in clinical practice by widening major bottlenecks in
analysis of somatic variants, while simultaneously increasing the accuracy and the number of
clinically important variants identified.
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Preface
Purpose
The purpose of this guide is to introduce the manual review process to standardize the process. It
describes how to download and use the Integrative Genomic Viewer (IGV), how to download
and use the IGV Navigator, and how to call variants.

What is Manual Review
When tumor DNA is sequenced and aligned to the reference genome, the next step to analyze its
somatic profile involves calling single nucleotide variants (SNVs) and short insertions and
deletions (indels) that are present in the tumor. This is done by comparing its genome to a
matched normal DNA sequence (usually blood for solid tumors and skin or buccal swab for
liquid tumors) to identify differences specific to the tumor. SNVs and indels are detected by
‘variant callers,’ or software tools that scan the tumor and normal genomes to identify somatic
variants. These are then filtered through pipelines and annotated to generate a confident list of
SNVs and indels for the analyst to review.
There are limitations in variant calling due to the challenges and inaccuracies that occur during
sample preparation, sequencing, and alignment, as well as fundamental genomic differences
across individuals. To identify these errors, the analyst pursues a process of manual review. This
process involves manually looking at each individual SNV and indel called and filtered in our
pipeline and labeling it confidently as a real somatic variant (true positive) or a false positive for
reasons related to sequencing and alignment errors. Given that there is some ambiguity in the
process there is also the ability to call variants as a possible somatic variant.

Why Is Manual Review Important?
Variants called during manual review are used to finalize the somatic call set. Correctly calling
true somatic variants is important for downstream analysis of the tumor. Somatic variants can be
used to understand tumor dynamics, change treatment protocol, or compare to other tumor types.
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Introduction
What is Integrative Genomics Viewer
The Integrative Genomics Viewer (IGV) is a high-performance visualization tool for analysis of
large genomics datasets. It supports array-based as well as massively parellel sequence data with
genomic annotations. It is used to conduct manual review of variants identified by somatic
variant callers. The IGV has been supported by funding from the National Cancer Institute, the
National Institutes of Health, the Informatics Technology for Cancer Research of the NCI, and
the Starr Cancer Consortium. To cite IGV in publications please use the following citations:
James T. Robinson, Helga Thorvaldsdóttir, Wendy Winckler, Mitchell Guttman, Eric S. Lander,
Gad Getz, Jill P. Mesirov. Integrative Genomics Viewer. Nature Biotechnology 29, 24–26
(2011). [PUBMED]
Helga Thorvaldsdóttir, James T. Robinson, Jill P. Mesirov. Integrative Genomics Viewer (IGV):
high-performance genomics data visualization and exploration. Briefings in Bioinformatics 14,
178-192 (2013). [PUBMED]
How to Download IGV
The IGV Desktop Application can be accessed at http://software.broadinstitute.org/software/igv/
The IGV Downloads Page can be accessed at
http://software.broadinstitute.org/software/igv/download
How to Use IGV
The IGV User Guide can be accessed at
http://software.broadinstitute.org/software/igv/UserGuide
Helpful IGV Definitions:
Track = IGV displays data in horizontal rows called tracks. Typically, each track represents one
sample or experiment.
Read Strand = Tracks are composed of read strands. Each read represents one molecule that was
sequences and analyzed. Reads are mapped to the reference genome and differences in the read
versus the reference genome are shown.
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What is IGV Navigator
IGV Navigator (IGV Nav) is a tool developed at the Griffith Lab to assist in analyzing variants
during manual review. Its input is a text file with variant coordinates and its output provides an
annotation of these variant coordinates. This annotation includes the call (i.e. somatic, germline,
ambiguous, or fail), tags to provide additional information if a variant is called ambiguous or fail,
and a notes section for free text.
How to Download IGV Nav
IGV Nav can be downloaded from the Griffith Lab GitHub Repo
(https://github.com/griffithlab/igvnav). Directions for download can be viewed
When using IGVNav for Mac, the program can be downloaded (IGVNav.zip), unzip and added
to Applications/ folder.

How to Use IGV Nav
Input file
The input file for IGVNav is a five column bed file and accepts both 0- and 1-based genomic
coordinates. The five columns correspond to chromosome, start coordinate, stop coordinate,
reference allele, and called variant allele for each SNV and indel. The application requires the
input file to contain a header line. This line will be replaced with a heading by the application
upon opening.
**Warning: If you do not provide a header, it will silently overwrite your first variant.**
Navigation by IGVNav
IGV MUST be open before opening IGVnav. It operates by commanding IGV to move to the
variant’s corresponding genomic position in the IGV session.
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IGVNav Interface
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Step-by-Step: Setting up and IGV_2.3.79 Session
Step 1: Open an IGV Session
Step 2: Load Tracks (BAM files)
If you have a file accessible via URL: File > Load from URL... > input URL
If you have a locally accessible file: File > Load from File… > input file
Step 3: Load Additional Tracks
If you have a tumor only session, we recommend loading Common SNPs:
File > Load from Server… > Annotations > All Snps 1.4.2
Step 4: Color Tracks by Read Strand
Right click on each sample track loaded > Color Alignments by > read strands
Step 5: View Reads as Pairs
Right click on each sample track loaded > Make sure “view is pairs” is checked
Step 6: Open IGV Nav Session
Step 7: Load Variant File
Open file associated with IGV session. Variant file must be a tab separated file with the
following columns: chr, start, stop, ref, var, call, tags, notes
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Types of Analysis
Tumor Sample Only
If only tumor (DNA) is available, the normal track will not be loaded within the IGV session.
True somatic variants must be determined by evaluating only the tumor DNA.
Note: It may be helpful to load a population SNP track within your IGV session to reduce the
number of SNPs common in the human population (e.g. 1000 Genomes, ExAC). Somatic
mutations are generally associated with lower frequencies in the human population.

Tumor Sample + Normal Sample
When tumor DNA and normal DNA are available they will both be loaded within the IGV
session. This increases the ability to label true somatic variants during manual review due to the
comparison with the normal track(s).
Note: Liquid tumor types might have tumor contamination in the normal tracks. Refer to Tumor
Normal (TN) variant for information on how to call these variants.

Tumor Sample + Normal Sample + Other (RNAseq, Relapse, Metastasis)
When tumor DNA, normal DNA and other DNA or RNA are available, they will all be loaded
within the IGV session. Any support from other tracks increases the likelihood that the variant
called is a somatic variant. Support from RNA sequencing data can be especially convincing and
should be used to confirm somatic calls in expressed genes.
Note: Multiple tracks can be loaded into the same IGV session, however, increasing the total
number of tracks will increase the time required for the IGV session to load. Downsizing the
number of visualized reads, or taking a sampling of reads, can assist in decreasing loading time.
This can be done using the IGV preferences pane. Warning: This should be considered when
evaluating low variant allele frequency variants as it may cause visual artifacts such as variant
support in reads in a single direction when in reality the variant is supported by reads in both
directions.
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Examples of Calls
Somatic Calls
The variant is a real somatic variant. No reads supporting the variant (green, “A”) are visible in
the normal sample.
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Germline Calls
The variant is also present in the matched normal sample, indicating that the variant is germline.
The variant was not somatic or specific to the tumor.

Helpful Hints:
*

Typically this variant is present with a Variant Allele Frequency (VAF) near 50% or 100%, indicating that
the germline polymorphism is either heterozygous (i.e. located on one allele) or homozygous (i.e. located
on both alleles) in both the tumor and the normal.

*

Bulk tumors are “contaminated” with normal cells. For this reason, 100% VAF in a non-purified tumor
sample at a site with good depth should be suspicious and likely a homozygous germline polymorphism.

*

If using GRCH38 you can view Common SNPs in the human genome, click:
“File” > ”Load from Server” > ”Annotations” > “Common Snps 1.4.2”
This will provide a “Common Snps 1.4.2” track that can be used to elucidate germline SNPs. If a variant in
the tumor is also present in the Common SNPs track then it is most likely germline.

*

If using GRCH37 you can view dbsnps 1.4.7 in the human genome, click:
“File” > ”Load from Server” > ”Annotations” > “dbsnps 1.4.2”
This will provide a “dbsnps 1.4.2” track that can be used to elucidate germline SNPs. If a variant in the
tumor is also present in the Common SNPs track then it is most likely germline.
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Failed Calls
The variant does not look real. Refer to the ‘Tags’ section to see reasons for labeling a variant as
a false positive.

Helpful Hints:
Using Tags and Notes can help you in why variants were given failed calls.
Make sure you set up your IGV sessions to be able to easily pick up certain types of variants like
“Directional” or “Short Inserts Only”. This requires coloring by read strand and viewing as pairs.
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Ambiguous Calls
The variant could be a real somatic variant, but the reviewer is not confident due to features of
the variant called and corresponding reads. Refer to ‘Tags’ to see reasons to define ambiguity. In
this case, the variant has support from one normal read and 3 short insert read pairs (denoted by
the white line in the middle of the read that shows that there are two overlapping reads from the
same read pair at this position). The DNA fragment was too small for sequencing from each end
to provide non-overlapping information about the sequence and commonly observed in DNA
derived from archived (FFPE) material. The variant count for this position will be 7 (1 normal
read and 6 short insert reads); however these reads were derived from a maximum of 4
independent DNA fragments. In this way short inserts can inflate variant counts and throw off
variant callers.
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Examples of Tags
Adjacent Indel (AI)
An adjacent indel (insertion or deletion) is an artifact that is induced by a nearby true somatic
variant. Typically, there is an insertion or a deletion near the artifact that induces a failure to
align the reads properly to the reference genome.

Helpful Hints:
To adequately catch this artifact, it is necessary to zoom out on the IGV session to ensure that
you visualize the adjacent insertion or deletion.
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Ambiguous Other (AO)
Ambiguous other is used to define a variant surrounded by inconclusive genomic features that
can’t be explained by the other tags available. For example, genomic regions with increased A/T
or G/C content that are not contained within tandem or dinucleotide repeats. This could also be
described as a low complexity region. If the Ambiguous Other tag is used, it is highly
recommended to include a short description in the Notes section.
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Directional (D)
A directional artifact is when the variant being evaluated can only be found on reads that are
sequenced in either the forward or the reverse direction. Typically, this is caused by strand bias
during sequencing. To properly visualize the directional artifacts, you must make sure the IGV
tracks are colored by read strand.

Helpful Hints:
To adequately catch this artifact, it is necessary to color the alignments by readstrand:
Right click on the track you want to color > click “Color alignments by” > click “read strand”
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Dinucleotide Repeats (DN)
The dinucleotide repeat artifact refers to when the reference sequence contains a region
alternating between two nucleotides (e.g. ATATAT…). The variant being evaluated may be a
SNV or indel directly adjacent or within this region and called due to misalignment or ends of
reads. Repeat regions are areas where some sequencers, particularly those dependent on the
polymerase enzyme, are prone to making mistakes. However, it is important to note that these
are areas of normal human variation and real de novo mutations due to errors produced by
polymerase during DNA replication. Other factors such as the size of the repeat, appearance in
the normal and indels of varying length should be considered during evaluation.

Helpful Hints:
Typically, these variants are small deletions or small insertions and they are usually visualized in
the both the tumor tracks and the normal tracks.
Although the variant being evaluated may be a 2bp deletion, deletions of different sizes or even
insertions are often observed with artifacts.
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Ends (E)
The variant called is only present close to the end (within 10 base pairs) of the variant-supporting
reads. There are no or few reads supporting the variant that contain the variant with high
concordance with the surrounding reference sequence.

Helpful Hints:
To adequately catch this artifact, it is necessary to zoom out on the IGV session to ensure that
you visualize the ends of the reads.
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High Discrepancy Region (HDR)
When a variant is present in reads that also have many mismatches, and the mismatches across
the whole track or in multiple tracks are the same, we use the High Discrepancy Region tag.
HDR occurs when there are homologs across the genome and mis-mapping of the reads to
homologs causes an apparent variant when they merely represent differences between the
homologs and alignment artifacts.

Helpful Hints:
This is distinguished from Multiple Mismatches (MM) by the similarities of the mismatches
across multiple tracks. In this example, all tracks contain the exact same mismatches at the same
loci in the genome.
If there are multiple variants in a row that only 10-20 bases apart in the same gene then you
should zoom out and make sure that you are not within an HDR.
Be sure that this is not due to adjacent SNPs. Clusters of common SNPs can happen and be real.
It is unlikely that a truly somatic variant would be observed on both alleles of a heterozygous
SNP; therefore, reads supporting a variant should also support only 1 allele of the heterozygous
SNP (be in linkage with one allele). This is another instance when having a track identifying
common polymorphisms can be helpful.
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Low Count Normal (LCN)
There is insufficient coverage in the normal sample to effectively compare the tumor sample.
This can be assessed by clicking on the loci in the coverage track to reveal the total number of
reads. Typically, we require at least 20X coverage in both tumor and normal to be sure that a
manual review call is a true somatic variant.
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Low Count Tumor (LCT)
Coverage in the tumor is lower than the average. This threshold is experiment-specific. Low
coverage at the site containing the variant will inflate the frequency associated with the variant
called.

150

Low Mapping (LM)
The mapping quality of a read, when the reads are “colored by strand,” is indicated by the
opacity of the read. Lighter reads have lower mapping quality, while darker reads have higher
mapping quality. This value can also be obtained by clicking on a read for its information. By
default, reads with a mapping quality of 0 are transparent, indicating they map to multiple
regions in the genome and cannot be used to accurately call a somatic variant at this locus. Reads
are colored if they have a mapping quality of >0. This threshold can be changed in View >
Preferences > Alignments > Mapping Quality Threshold.

Helpful Hints:
Regions with numerous reads with a mapping quality of 0 are often associated with genes with
other homologs in the genome and therefore HDRs (see this call type above) and result in low
mapping quality reads in both the normal and tumor.

151

Low Variant Frequency (LVF)
The Low Variant Frequency tag is used when there are some reads of support for the variant, but
the variant allele frequency (VAF) is relatively low. To quickly assess the VAF, you can click on
the coverage track to pull up the total read counts, the number of reads for each base and the
support for different directions. Usually, the LVF must be used in conjunction with other tags to
fail the variant.

Helpful Hints:
The coverage track will be colored according to base when a variant is present at a 15% VAF, by
default. This cutoff can be changed by altering this threshold in View > Preferences >
Alignments > Coverage allele-fraction threshold. This can be particularly helpful with high depth
samples.
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Multiple Mismatches (MM)
The multiple mismatches tag is used when the reads that contain the variant have other
mismatched base pairs, indicating a less trustworthy read. This is like the HDR tag; however, it
can include mismatches that are not exactly the same across the reads.

Helpful Hints:
The mismatch base color becomes more transparent as the base quality gets lower, so if the
adjacent mismatch is dark in color, then you have reduced confidence in that read being properly
sequenced and/or aligned to the reference genome.
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Mononucleotide (MN)
The mononucleotide repeat artifact refers to when the reference sequence contains a region of a
single nucleotide (e.g. AAAAAAA…). The variant being evaluated may be a SNV or indel
directly adjacent or within this region and called due to misalignment or ends of reads. Repeat
regions are areas where some sequencers, particularly those dependent on the polymerase
enzyme, are prone to making mistakes. However, it is important to note that these are areas of
normal human variation and real de novo mutations due to errors produced by polymerase during
DNA replication. Like the Dinucleotide (DN) tag, other factors such as the size of the repeat,
appearance in the normal and indels of varying length should be considered during evaluation.

Helpful Hints:
Typically, these variants are small deletions or small insertions and they are usually visualized in
the both the tumor tracks and the normal tracks.
Although the variant being evaluated may be a 1bp deletion, deletions of different sizes or even
insertions are often observed with artifacts.
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Multiple Variants (MV)
The Multiple Variants artifact is used If the variant called has reads supporting multiple different
variants at the same loci. In the example shown, there were calls for all four different nucleotides
at the same loci, making it an unreliable call.

Helpful Hints:
Make sure you scroll all the way to the bottom of the track to visualize all the reads. It is not
enough just to rely on the coverage coloring as there might be multiple variants that have a VAF
too small to be represented in the coverage bar.
Clicking the coverage track will give you the relative abundance of each base at that site.
For very deep data, multiple variants due to random error will start to accumulate. The relative
abundance of each base should be considered in cases with deep coverage.
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No Coverage in Normal (NCN)
There is no coverage in the normal sample to effectively compare the tumor sample. This can
occur when you do not have a normal track for comparison or you do not have any reads in the
normal track that help assess if the variant is true. Typically, we require at least 20X coverage to
be sure that a call is truly somatic.
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Short Inserts (SI) and Short Inserts Only (SIO)
Short inserts refer to instances when the DNA fragment is small enough that sequencing from
each end of the molecule results in overlapping reads. Variants supported by reads produced
from these short fragments result in the appearance of 2 reads supporting this variant when in
reality they represent a single molecule of DNA, inflating the VAF of the variant. Support for the
called variant is present in both reads of a read pair and other reads (SI) or support for the called
variant is ONLY present in paired reads with a short insert size (SIO). That is, the variant
appears in the overlapping region of the two read fragments, indicated by the line through the
middle of the reads. These are prevalent in data derived from archival material (FFPE) or other
source material with short DNA fragments (cell-free DNA). Artifacts are generally present at
lower frequencies, and are present in two or three read pairss, or (four to six readfragments in
total).

Helpful Hints:
To visualize short insert variants you must view the tracks as pairs. Short inserts will be
condensed and a grey line indicates the areas where these reads overlap.

157

Same StartEnd (SSE)
The Same Sitart/End artifact occurs when the variant is only contained by reads that start and
stop at the same loci. This is typically attributed to a variant called in multiple reads created from
the same molecule during the amplification process in the genome sequencing protocol, but
erroneously not removed during read de-duplication.

Helpful Hints:
Make sure you sort by the variant and zoom out to show the entire length of the reads. This will
allow you to visualize if the read ends line up.
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Tumor in Normal (TN)
Tumor in normal can occur if the variant has reads of support in the normal tracks. This is a
common occurrence in blood tumors (leukemia and lymphoma) as well as tumors that are highly
metastatic. Although this might not be a reason for failing the variant call, it can be used in cases
of ambiguity to denote reasons for potential failure. Variants created by sequencing or alignment
artifacts will often occur in both the tumor and the normal sample.

Helpful Hints:
This does not occur in all hematopoietic tumors but is likely when tumor cells are circulating in
the blood stream such as acute myeloid leukemias with high blast counts.
Evaluating other normal samples from your cohort can help differentiate sequencing and pipeline
artifacts from normal contamination.
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Tandem Repeat (TR)
The tandem repeat artifact refers to when the reference sequence contains a region alternating
between three nucleotides (e.g. CAGCAGCAG…). The variant being evaluated may be a SNV
or indel directly adjacent or within this region and called due to misalignment or ends of reads.
Repeat regions are areas where some sequencers, particularly those dependent on the polymerase
enzyme, are prone to making mistakes. However, it is important to note that these are areas of
normal human variation and real de novo mutations due to errors produced by polymerase during
DNA replication. Like the Mononucleotide (MN) and Dinucleotide (DN) tags, other factors such
as the size of the repeat, appearance in the normal and indels of varying length should be
considered during evaluation.

Helpful Hints:
Typically, these variants are small deletions or small insertions and they are usually visualized in
the both the tumor tracks and the normal tracks.
Although the variant being evaluated may be a 3bp deletion, deletions of different sizes or even
insertions are often observed with artifacts.
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Appendix 2: Features Used in Manual
Review Classifier
Feature
disease_AML

Description
Disease label = AML

disease_AML

Disease label = AML

disease_GST

Disease label = GIST

disease_MPNST

Disease label = Malignant Peripheral Nerve Sheath Tumors

disease_SCLC

Disease label = Breast Cancer

disease_breast

Disease label = Colorectal Cancer

disease_colorectal
disease_glioblastoma

Disease label = Glioblastoma
Disease label = Lymphoma

disease_lymphoma

Disease label = AML

disease_melanoma

Disease label = Melanoma

normal_VAF
normal_depth
normal_other_bases_count
normal_ref_avg_basequality
normal_ref_avg_clipped_length
normal_ref_avg_distance_to_effective_3p_end
normal_ref_avg_distance_to_q2_start_in_q2_read
s
normal_ref_avg_mapping_quality

Variant allele frequence of normal reads
Depth of normal reads
Count of non ref/var reads in normal
Average basequality of reference reads in normal
Average clipped length of reference reads in normal
Average distance to 3' end of reference reads in normal
Average distance to a run where Illumina's Read Segment
Quality Control Indicator=2. False positives more commonly
appear near these regions.
Average mapping quality for reference reads in normal

normal_ref_avg_num_mismaches_as_fraction

Average number of mismatches on these reads per base

normal_ref_avg_pos_as_fraction

Average position on the read as a fraction. This value is
normalized to the center of the read
Mean single ended mapping quality

normal_ref_avg_se_mapping_quality
normal_ref_avg_sum_mismatch_qualities
normal_ref_count
normal_ref_num_minus_strand
normal_ref_num_plus_strand
normal_ref_num_q2_containing_reads
normal_var_avg_basequality
normal_var_avg_clipped_length
normal_var_avg_distance_to_effective_3p_end
normal_var_avg_distance_to_q2_start_in_q2_read
s
normal_var_avg_mapping_quality
normal_var_avg_num_mismaches_as_fraction

Average sum of the base qualities of mismatches in the reads
Counts of reference basepairs in normal
Average minus strand reference reads in normal
Average plus strands reference reads in normal
Number of reads containing a run where Illumina's Read
Segment Quality Control Indicator=2. False positives more
commonly appear near these regions.
Average basequality of variant reads in normal
Average clipped length of var reads in normal
Average distance to 3' end of var reads in normal
Average distance of position (as fraction of unclipped read
length) to the start of the q2 run
Average mapping quality for var reads in normal
Average number of mismatches on these reads per base
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normal_var_avg_pos_as_fraction
normal_var_avg_se_mapping_quality
normal_var_avg_sum_mismatch_qualities
normal_var_count
normal_var_num_minus_strand
normal_var_num_plus_strand
normal_var_num_q2_containing_reads

Average position on the read as a fraction. This value is
normalized to the center of the read
Mean single ended mapping quality
Average sum of the base qualities of mismatches in the reads
Average count for var reads in normal
Average minus strand var reads in normal
Average plus strand var reads in normal

reviewer_1

Number of reads containing a run where Illumina's Read
Segment Quality Control Indicator=2. False positives more
commonly appear near these regions.
Call from reviewer 1

reviewer_2

Call from reviewer 2

reviewer_3

Call from reviewer 3

reviewer_4

Call from reviewer 4

tumor_VAF

Variant allele frequence of tumor reads

tumor_depth
tumor_other_bases_count
tumor_ref_avg_basequality
tumor_ref_avg_clipped_length
tumor_ref_avg_distance_to_effective_3p_end
tumor_ref_avg_distance_to_q2_start_in_q2_reads
tumor_ref_avg_mapping_quality

Depth of tumor reads
Average count of non ref/var bases in tumor
Average basequality of reference reads in tumor
Average clipped length of ref reads in tumor
Average distance to effective 3' end in ref tumor
Average distance to a run where Illumina's Read Segment
Quality Control Indicator=2. False positives more commonly
appear near these regions.
Average mapping quality of reference reads in tumor

tumor_ref_avg_num_mismaches_as_fraction

Average number of mismatches on these reads per base

tumor_ref_avg_pos_as_fraction

Average position on the read as a fraction. This value is
normalized to the center of the read
Mean single ended mapping quality

tumor_ref_avg_se_mapping_quality
tumor_ref_avg_sum_mismatch_qualities
tumor_ref_count

Average sum of the base qualities of mismatches in the reads
Counts of reference basepairs for tumor sample

tumor_ref_num_minus_strand

Number of negative read strands in tumor ref calls

tumor_ref_num_plus_strand

Number of positive read strands in tumor ref calls

tumor_ref_num_q2_containing_reads
tumor_var_avg_basequality
tumor_var_avg_clipped_length
tumor_var_avg_distance_to_effective_3p_end
tumor_var_avg_distance_to_q2_start_in_q2_reads
tumor_var_avg_mapping_quality

Number of reads containing a run where Illumina's Read
Segment Quality Control Indicator=2. False positives more
commonly appear near these regions.
Average basequality of variant reads in tumor
Average clipped length of var reads in tumor
Average distance to 3' end of var reads in tumor
Average distance to a run where Illumina's Read Segment
Quality Control Indicator=2. False positives more commonly
appear near these regions.
Average mapping quality of a tumor variant reads

tumor_var_avg_num_mismaches_as_fraction

Average number of mismatches on these reads per base

tumor_var_avg_pos_as_fraction

Average position on the read as a fraction. This value is
normalized to the center of the read
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tumor_var_avg_se_mapping_quality
tumor_var_avg_sum_mismatch_qualities
tumor_var_count

Mean single ended mapping quality
Average sum of the base qualities of mismatches in the reads
Counts of variant basepairs for tumor sample

tumor_var_num_minus_strand

Number of negative read strands in tumor var calls

tumor_var_num_plus_strand

Number of positive read strands in tumor var calls

tumor_var_num_q2_containing_reads
disease_GST

Number of reads containing a run where Illumina's Read
Segment Quality Control Indicator=2. False positives more
commonly appear near these regions.
Disease label = GIST
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Appendix 3: High overlap between false
negatives recovered by the machine learning
classifiers and CIViC annotations.
For each table, the ‘Confidence’ is the well-scaled probability of the call being labeled as
somatic, the ‘MR Call’ is the call made by the human manual reviewer, the ‘model Call’ is the
call made by the deep learning model, and ‘CIViC Score’ represents the quality of evidence
within CIViC based on number of evidence statements and trust rating. A. This table shows false
negative calls that had overlap with CIViC annotations. B. This table shows false positive calls
that had overlap with CIViC annotations.
A
False Negative Overlap with CIViC
Chr

Start

Stop

Ref

Var

Gene

Disease

1

115258747

115258747

C

G

NRAS

AML

2

209113112

209113112

C

T

IDH1

AML

1

115258747

115258747

C

T

NRAS

AML

19

33793237

33793238

-

CCGC

CEBPA

AML

17

7578196

7578196

A

T

TP53

AML

17

74732959

74732959

G

T

SRSF2

AML

12

49424359

49424359

C

A

KMT2D

breast

12

49432313

49432313

C

T

KMT2D

breast

13

32972788

32972788

C

T

BRCA2

breast

21

36228727

36228727

G

A

RUNX1

breast

12

49431112

49431112

G

A

KMT2D

breast

12

49437569

49437569

T

C

KMT2D

breast

12

49440556

49440556

C

T

KMT2D

breast

13

49037971

49037971

G

A

RB1

breast

17

37872148

37872148

A

G

ERBB2

breast

17

41258453

41258453

A

G

BRCA1

breast

12

49445051

49445051

G

A

KMT2D

breast
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Confidence
0.8906972
41
0.8356539
61
0.9317687
75
0.4667634
96
0.4988112
15
0.5825120
21
0.4992055
3
0.8855612
28
0.6114878
06
0.8724330
66
0.7002339
36
0.5714657
31
0.5239250
06
0.9911405
44
0.6592773
2
0.7609889
51
0.4834785
46

MR
Call

Modell
Call

Evidence
Items

CIViC
Score

f

s

17

174

f

s

11

16

a

s

17

174

a

s

8

110

f

s

2

28

a

s

1

20

a

s

1

12

a

s

1

12

a

s

18

228

a

s

6

88

a

s

1

12

a

s

1

12

a

s

1

12

a

s

3

20

a

s

2

25

a

s

11

148

a

s

1

12

12

49426772

49426777

GCT
GCT

-

KMT2D

breast

12

49431959

49431959

C

T

KMT2D

breast

17

29685594

29685594

G

A

NF1

breast

17

74732942

74732942

T

C

SRSF2

AML

4

106190898

106190898

C

A

TET2

AML

4

55598158

55598158

C

A

KIT

AML

9

9425502

9425502

G

T

PTPRD

SCLC

19

1220655

1220655

G

-

SCLC

9

139418369

139418369

C

G

STK11
NOTCH
1

3

178936091

178936091

G

A

PIK3CA

breast

3

178936103

178936103

G

A

PIK3CA

breast

7

124538437

124538437

A

-

POT1

breast

22

42523636

42523636

C

A

CYP2D6

breast

12

49431045

49431045

G

A

KMT2D

breast

22

42524327

42524327

A

G

CYP2D6

breast

22

42523636

42523636

C

A

CYP2D6

breast

22

38379767

38379767

C

G

breast

2

25457243

25457243

G

A

SOX10
DNMT3
A

4

55561907

55561907

C

G

KIT

AML

4

55564663

55564663

T

G

KIT

AML

4

55564702

55564702

C

T

KIT

AML

2

209113113

209113113

G

A

IDH1

22

42522550

42522550

G

A

CYP2D6

AML
glioblas
toma

SCLC

AML
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0.6494603
75
0.7337821
72
0.5976935
63
0.5126011
37
0.9470288
16
0.9186456
2
0.6759339
57
0.5013615
49
0.9243088
96
0.9370706
68
0.9481272
7
0.7084913
25
0.5104254
48
0.8837848
31
0.3917511
11
0.6050271
39
0.7890682
22
0.8630380
63
0.7486454
84
0.8832876
68
0.9042010
9
0.6730701
92
0.6440299
75

a

s

1

12

a

s

1

12

a

s

8

56

a

s

1

20

a

s

6

96

a

s

3

24

a

s

1

6

a

s

6

44

a

s

1

4

a

s

37

195

a

s

19

146

f

s

1

12

a

s

1

16

a

s

1

12

a

s

1

16

a

s

1

16

a

s

1

8

a

s

28

411

f

s

3

24

a

s

3

24

a

s

3

24

a

s

17

68

a

s

1

16

B
False Positive Overlap with CIViC
Chr
13
2

4
9

19
21
17
2
17
9
17

4
17
12
17
17
17
21
5
12
21
12
21

Start
2860
9758
2091
1311
3

Stop
286097
58

5558
9770
5073
770

555897
71
507377
0

3379
2395
3620
6887
7577
602
2545
7243
2966
5755
9822
0365
7578
190
1061
5607
2
7473
3070
4943
3619
2965
4591
4122
3066
4124
5274
3617
1722
6752
2556
4943
2165
3616
4787
4942
1834
3616
4642

209113
113

337923
96
362068
87
757760
2
254572
43
296657
56
982203
65
757819
0
106156
072
747330
70
494336
19
296545
91
412230
66
412452
74
361717
22
675225
56
494321
65
361647
87
494218
34
361646
42

Ref

Var

Gene

Disease

C

G

FLT3

AML

Confide
nce
0.00896
0945

G

A

IDH1

AML

0.25896
2572

-

AGGTG
GG

KIT

AML

G

T

JAK2

AML

-

CCACG
TTGCG
CTGCT
TGG

CEBPA

AML

T

A

RUNX1

AML

A

G

TP53

AML

G

T

DNMT3A

AML

-

A

NF1

AML

C

A

PTCH1

AML

T

C

TP53

AML

C

T

TET2

AML

G

A

SRSF2

AML

C

T

KMT2D

breast

C

T

NF1

breast

G

A

BRCA1

breast

C

A

BRCA1

breast

G

A

RUNX1

breast

G

A

PIK3R1

breast

C

T

KMT2D

breast

C

T

RUNX1

breast

G

A

KMT2D

breast

G

A

RUNX1

breast

166

0.38641
3515
0.27082
1482

0.30972
5046
0.13754
4215
0.10930
5017
0.40397
0242
0.00078
4582
0.09396
6253
0.25381
3058
0.30908
7753
0.13906
7724
0.46864
7331
0.14899
5921
0.24190
3991
0.27337
6912
0.27454
862
0.48558
706
0.41210
8928
0.43298
0925
0.40430
221
0.47896
9276

MR Call

Classifier
Call

Evidence
Items

CIViC
Score

s

f

4

43

s

f

17

68

s

f

3

24

s

a

5

70

s

a

7

104

s

a

6

88

s

a

2

28

s

a

28

411

s

f

8

56

s

a

1

16

s

a

2

28

s

a

6

96

s

a

1

20

s

a

1

12

s

a

8

56

s

a

11

148

s

a

11

148

s

a

6

88

s

a

1

4

s

a

1

12

s

a

6

88

s

a

1

12

s

a

6

88

21

17

3
17
17
19
21
15

17
17

19
12

4
4
1
1
12
14
12
17
17

3625
2919

362529
20

7473
2936
1789
2798
0
3761
9027
7577
538

747329
59

3379
2250
3616
4687
9063
1838

337922
55
361646
88
906318
38

7473
2936
7577
581

747329
59
757758
1

3379
3247
4942
2933
1532
4418
5
1532
4938
4
1118
4571
1118
4573
5647
8851
1052
4655
1
4944
4545
2953
3260
3787
9588

178927
981
376190
27
757753
8

337932
57
494229
33
153244
185
153249
384
111845
71
111845
73
564788
51
105246
551
494445
45
295332
60
378795
88

TAGCA
TTTCTC
AGCTC

RUNX1

AML

0.30429
3782

s

f

6

88

-

SRSF2

AML

0.13832
365

s

f

1

20

-

GTC

PIK3CA

breast

s

f

19

146

G

A

CDK12

breast

s

a

1

8

C

T

TP53

breast

s

a

5

60

s

f

7

104

s

f

6

88

s

f

3

28

s

f

1

20

s

a

2

28

s

f

8

110

s

a

1

12

s

a

2

10

s

a

4

26

s

a

1

6

s

a

2

10

s

a

1

12

s

a

5

35

s

a

1

12

s

a

8

56

s

a

2

25

GGC
GGC
TGT
GGT
GTG
AGT
CCG
GGG

0.37080
7111
0.03759
4032
0.48575
6129

GCA
GTT

-

CEBPA

AML

-

TC

RUNX1

AML

C
GGC
GGC
TGT
GGT
GTG
AGT
CCG
GGG

T

IDH2

AML

-

SRSF2

AML

A

T

TP53

AML

GCG
TGC
GGG
GG

-

CEBPA

AML

C

T

KMT2D

breast

0.10719
8857
0.14578
785

G

A

FBXW7

breast

0.13251
6399

C

T

FBXW7

breast

G

T

MTOR

breast

G

A

MTOR

breast

C

T

ERBB3

breast

C

T

AKT1

breast

G

A

KMT2D

breast

C

T

NF1

breast

A

G

ERBB2

breast

167

0.08289
7209
0.33057
0877
0.01297
0433

0.10793
8401
0.19551
4232

0.18640
0592
0.13387
543
0.11833
4189
0.32006
4127
0.32713
6993
0.31553
2327
0.08959
8835
0.05985
9622

4
17

2
5
5
12
12
6
13

5559
4177
4126
2680
2125
3788
9
6756
9746
6757
6437
4941
8629
4943
3883
4190
3845
4894
1711

555941
77
412626
80
212537
889
675697
46
675764
37
494186
29
494338
83
419038
45
489417
11

C

T

KIT

breast

G

A

BRCA1

breast

C

T

ERBB4

breast

G

A

PIK3R1

breast

C

T

PIK3R1

breast

C

T

KMT2D

breast

G

A

KMT2D

breast

C

G

CCND3

AML

A

T

RB1

SCLC

168

0.31102
1984
0.13068
6581
0.02291
0668
0.14323
5296
0.32190
4689
0.21499
0601
0.06100
0999
0.22497
4856
0.42579
8684

s

a

3

24

s

a

11

148

s

a

1

8

s

a

1

4

s

a

1

4

s

a

1

12

s

a

1

12

s

a

1

6

s

a

3

20

